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ABSTRACT
Health Literacy, Cognitive Impairment, and Medication Adherence in Veterans with
Heart Failure
Background: Heart failure (HF) affects 5.8 million people in the United States, costly in
terms of patient mortality and morbidity as well as healthcare dollars. One important
manifestation of poor HF outcomes is the excessive admission-readmission cycle. Non
adherence to medication is responsible for the majority of HF readmissions. Identification
and intervention for key factors contributing to poor medication adherence is critical to
improving outcomes. Two such factors prevalent in persons with HF are cognitive
impairment (Cl) and poor health literacy (HL). There is a paucity of tested interventions
designed to improve medication adherence by addressing underlying Cl or HL. A recent
study tested a pictorial medication sheet to improve medication adherence in veterans
with HF and Cl, however no information on HL was collected. This new study examines
what mediating effects HL may have played in the adherence scores of subjects in the
completed study.
Study Aims:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and
other key variables (including the intervention) have upon medication adherence in

cognitively impaired veteran outpatients with HF based on prior data from an
interventional study testing a pictorial medication sheet to improve medication
adherence.
Study Design
A retrospective, correlational, cross-sectional design was employed to analyze HL scores
from medical records with data from the completed study using conventional statistics
and structural equation modeling.
Results: 27 subjects with a mean age of 65.3 years (SD 8.2, range 45-80) had evaluable
data. HL was less than adequate in 19% of the sample. HL scores were strongly
correlated with cognition. HL did not significantly affect relationships between study
covariates (cognition scores, depression, number of medications) and medication
adherence.
Conclusions and Significance: HL scores were associated with cognitive function
scores. More research is needed to evaluate the prevalence and effect of poor HL in
veterans with HF upon adherence.
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Chapter 1: Introduction
Heart failure (HF) is a complex, chronic medical condition that affects 5.8 million
people in the United States, contributing significantly to increased morbidity, mortality,
healthcare expenditures, and decreased quality of life (Lindenfeld et al., 2010; LloydJones et al., 2010). This negative impact of HF is projected to escalate as the American
population ages, and is of particular importance to the Veterans’ Health Care System
(VA), the largest integrated healthcare system in the United States (Heidenreich, 2011;
Population Resource Center, 2011). Large clinical trials have demonstrated the success of
pharmacologic regimens and lifestyle strategies in improving patient outcomes and have
resulted in the development of consensus guidelines (Lindenfeld et al., 2010). However,
HF patients tend to be older with multiple comorbidities and may find it difficult to
follow these often-complex regimens, thereby losing the benefits of evidence-based care
(Heidenreich, 2004; Murray et al., 2007). One particularly important manifestation of
poor HF outcomes is the excessive admission-readmission cycle; in the VA system 20%
of HF patients are readmitted within 30 days (Heidenreich, 2011). Medication non
adherence is common in persons with HF, and has been shown to be responsible for the
majority of readmissions for HF in the United States (Albert, 2008; Esposito, Bagchi,
Verdier, Bencio, & Kim, 2009; Ho, Bryson, & Rumsfeld, 2009; Munger, Van Tassell, &
LaFleur, 2007; Murray, et al., 2009). Thus identification of, and intervention for, key
factors contributing to poor medication adherence has become a primary goal for
clinicians and healthcare policymakers.
1
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Medication Adherence
Adherence is a complex issue and depends on multiple patient and healthcarerelated factors. The World Health Organization’s Multidimensional Adherence Model
classifies predictors of poor adherence into five broad domains: socio-economic status,
type of healthcare system, prescribed therapy, condition being treated, and individual
patient-related factors (Sabate, 2003). However, this model explained less than 20% of
poor medication adherence in HF patients, emphasizing the need to identify other
contributors to non-adherence in this population (van der Wal & Jaarsma, 2008; Wu,
Moser, Chung, & Lennie, 2008). One frequently overlooked factor that may influence all
of these domains is the presence of cognitive impairment (Cl). Indeed, a recent study in
veterans with HF demonstrated a high prevalence (58%, n=251) of clinically
unrecognized Cl that was significantly associated with poorer medication adherence
(Hawkins et al., 2012).
Another factor associated with adherence is poor health literacy (HL). In
America, low health literacy is a highly prevalent and clinically under-recognized
problem that directly impacts patient’s self care skills (Morrow et al., 2006). Poor HL
predicts poor medication adherence, but little is known about the prevalence of poor HL
in veterans with HF, or the effect of HL on medication adherence in cognitively impaired
outpatients with HF (Evangelista et al., 2010; Moser & Watkins, 2008).
Interventions to Improve Adherence
There is a general lack of awareness on the part of providers in regards to the
prevalence of Cl and poor HL in their patients, and the contribution of these factors to

poor medication adherence (Cameron et al., 2010). Interventions that rely on traditional
models of patient education to improve adherence are thus likely to fail in this at-risk
population, and there is a paucity of tested interventions that improve outcomes by
improving medication adherence (Wu, Corley, Lennie, & Moser, 2012). Novel
interventions targeted at key factors contributing to non-adherence are urgently needed.
To address this gap, a pilot study (TARGET) was designed utilizing two
interventions addressing Cl as the underlying cause of medication non-adherence. The
TARGET study enrolled subjects with known Cl from an outpatient veteran HF clinic
and tested the effectiveness of an intervention to improve medication adherence
(Hawkins, Firek & Silvet, 2012). The intervention, a pictorial medication sheet, was
designed to address memory problems from underlying cognitive impairment. The
primary outcome, medication adherence, was measured from sequential direct 30-day pill
counts, using subjects as their own controls. A major limitation in the TARGET study is
that no information on HL was collected. HL may actually mediate the relationship
between key independent variables (including the intervention) and medication adherence
in this study.
Purpose of Study
The purpose of this dissertation research study was to estimate the causal
relationships between HL (included in existing outpatient medical records), the
intervention, other key variables, and medication adherence in a sample of cognitively
impaired outpatient veterans with HF who participated in an interventional pilot study

testing a pictorial medication sheet and alarmed pill box to improve medication
adherence.
Using previously-collected data from the TARGET pilot study and the existing
outpatient medical records of the TARGET participants, a retrospective, correlational,
cross-sectional study design using secondary data was used to answer the study research
question: What are the direct and indirect effects that HL and other key variables
(including the intervention) had upon medication adherence in cognitively impaired
veterans with HF?
Research Alms
The specific aims of the study were to:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and
other key variables (including the intervention) had upon medication adherence in
cognitively impaired veteran outpatients with HF based on prior data from an
interventional study testing a pictorial medication sheet and alarmed pillbox to improve
medication adherence.
Summary
Heart failure is an epidemic facing the American healthcare system, and is
projected to grow as the population ages (Heidenreich, 2011; Population Resource

Center, 2011). One manifestation of poor outcomes in HF is the excessive admissionreadmission cycle. This is particularly important to the VA healthcare system wherein
20% of veterans with HF are readmitted within 30 days (Heidenreich, 2011). Non
adherence to medication has been shown to be both prevalent in persons with HF, and
responsible for the majority of hospital readmissions (Albert, 2008; Esposito, Bagchi,
Verdier, Bencio, & Kim, 2009; Ho, Bryson, & Rumsfeld, 2009; Munger, Van Tassell, &
LaFleur, 2007; Murray, et al., 2009). Two key factors in poor medication adherence
include poor HL and Cl (Hawkins, 2012; Morrow, 2006). A recent pilot study was
designed to target Cl as an underlying cause of medication non-adherence; a major
limitation was that no information on HL was collected as part of that study. HL may
actually have mediated the relationship between key independent variables (including the
intervention) and the outcome measure of medication adherence. This study sought to
answer the research question: what are the direct and indirect effects that reading HL and
numeracy HL and other key variables (including the intervention) had upon medication
adherence in cognitively impaired veteran outpatients with HF based on prior data from
an interventional study testing a pictorial medication sheet and alarmed pillbox to
improve medication adherence?

Chapter 2: Review of the Literature
This chapter includes a survey of the relevant current literature to provide a
context for the study. The research will be situated within an existing theoretical
framework, and a brief concept analysis will be included to clarify the main construct of
“adherence”. The relationships between the study and previous work conducted on the
topic will be evaluated, and the current gap in the knowledge that this study sought to
answer will be described.
Conceptual Model
The use of a theoretical model helps describe complex systems, and ensures
appropriate variables are studied when designing research and clinical interventions.
Riegel and Dickson (2008) propose a conceptual model of HF self-care. This model
described HF self-care in five stages: stage one: self-care maintenance (symptom
monitoring and treatment adherence) and stages two through five: self-care management
(recognition of, response to, and evaluation of symptoms). Each stage involves a series of
naturalistic, or “real world”, decisions made by the patient. Adherence is viewed as only
one part of the multifaceted self-care process (Riegel et al., 2009). The authors consider a
separate construct, self-care confidence, as moderating and/or mediating all five stages in
the model (Riegel & Dickson, 2008).
The HF self-care model was selected to serve as the theoretical framework for this
dissertation research as it reflects the complex and iterative nature of daily decisions
made by persons living with HF regarding their treatment plan. The presence of Cl and/or

poor HL may exert an influence on decision-making at any of the five stages in the
model, as well as on the construct of self-care confidence. For the purpose of this study
the influence of Cl and/or poor HL will be addressed as primarily affecting stage one:
treatment adherence, specifically, medication adherence.
Figure 1. Conceptual Model

Self-Care of Heart Failure Model
Self-care Maintenance

Self-care Management

Stag* 1
Symptom monitoring

Self-care Confidence
Figure 1. HF self-care in five stages: stage one: self-care m aintenance (symptom

monitoring and treatm en t adherence) and stages tw o through five: self-care
m anagem ent (recognition of, response to, and evaluation of symptoms). Each stage
involves a series of naturalistic decisions made by th e patient. Adherence is viewed as
only one part of th e multifaceted self-care process. The construct of self-care
confidence m oderates and/or m ediates th e self-care process. From "A Situation-specific
Theory of Heart Failure Self-care," by B. Riegel and V. V. Dickson, 2008, Journal of
Cardiovascular Nursing, 23, p. 192. Copyright 2008 by Lippincott, Williams & Wilkins.
Reprinted with permission.

Adherence
Adherence is frequently used to replace an older term, “compliance”, when
describing the relative success of a patient in following a plan of care. Adherence

suggests a more active, independent role on the part of the patient; compliance is thought
to reflect a more paternalistic attitude towards a passive patient (Aronson, 2007; Gould &
Mitty, 2010). Closely related to adherence and compliance is a newer term:
“concordance”. Concordance reflects the ideal partnership between an empowered patient
and enlightened provider jointly formulating a plan of care (Carpenter, 2005; Edwards,
Davies, & Edwards, 2009). Each of these three terms, when examined closely, gives
inference as to why the patient may not successfully follow the plan of care:
1. Non-compliant: patient choosing to not ‘obey’ the given plan.
2. Non-adherent: something interferes with the ability to adhere, although the intent
may be there.
3. Discordant: the patient and the provider did not arrive a mutually agreeable plan.
There is much discussion in the literature regarding the usage of these closely
related terms and they are often used interchangeably in journal articles and in clinical
practice (Carpenter, 2005). However, adherence is the most frequently used term, and
was term chosen by the World Health Organization (Sabate, 2003) and the U.S. National
Institute of Health (Adherence Research Network, 2010). In addition, this dissertation
research will examine how underlying Cl and/or poor HL influence the person’s ability to
adhere, which most closely matches inference number two, above. Therefore, the term
“adherence” will be used in this research proposal.
Importance of medication adherence in HF outcomes
The American healthcare system is facing unprecedented challenges in the
demand for and the delivery of care. A key driving force behind many of these changes

is the rapidly aging population; by 2030, there will be about 72.1 million persons over 65
years old, more than twice the number in 2000 (US Department of Health and Human
Services, 2012). This shift in demographics brings along an attendant rise in the multiple
and progressive chronic diseases often seen in the elderly (Population Resource Center,
2011).
HF serves as an archetypical disease to illustrate these transformational changes
in American healthcare. HF has been termed an epidemic due to the increasing numbers
of cases, the intensity of care they require, and the direct and indirect costs incurred
(Heidenreich, 2011; Lloyd-Jones et al., 2010). Admissions for HF in a recent review of
Medicare data showed high in-hospital mortality (4.4%) and high readmission rates;
specifically, 60% of patients had one or more readmission for any cause within the first
nine months, and 28% were readmitted for heart failure (Aranda, Johnson, & Conti,
2009). In the VA system, up to 20% of patients are readmitted for HF within 30 days
(Heidenreich, 2011). This high rate of hospitalization has led to cost estimates of over
$37 billion for heart failure care in the VA alone (Heidenreich, 2011). Many of these
readmissions may have been prevented if patients were to engage in consistent self-care
including adherence to medication (Cutler & Everett, 2010; Heidenreich, 2004; Riegel et
al., 2009). Poor adherence to medication in persons with HF is common, with estimates
ranging from 33 from 58% (Albert, 2008; Cutler & Everett, 2010; Heidenreich, 2004;
Ho, Bryson & Rumsfeld, 2009; Wu, Moser & De Jong, 2009). Healthcare stakeholders
recognize this; non-adherence has been termed the next frontier in quality improvement
in cardiovascular outcomes research (Heidenreich 2004).

Medication non-adherence in persons with HF. Non-adherence to medication may be
the most common cause of HF exacerbations and subsequent hospital readmissions in the
United States today; and this is quoted widely in the literature. However, when sources of
this quote are closely examined it appears that the reported outcomes, such as hospital
readmissions, are often in reference to cardiovascular disease (e.g. hypertension, coronary
artery disease, or myocardial infarction) rather than HF alone. (Albert, 2008; Cutler &
Everett, 2010; Osterberg & Blaschke, 2005). However, this is not unreasonable as
hypertension, coronary artery disease, and prior myocardial infarction are the most
common pre-disposing etiologies of HF in America (Lindenfeld et al., 2010).
Esposito et al. (2009) examined medication adherence in persons with HF with
healthcare usage and costs in Medicare and Medicaid data in four states. This study
showed improved medication adherence was related to fewer hospitalizations and
emergency room visits, and that overall treatment costs for those with 95% medication
adherence were 15% less than those with adherence between 80 and <.95%; p = < .01
(Esposito, Bagchi, Verdier, Bencio, & Kim, 2009). Murray et al. (2009) studied
pharmacy refill data in a cohort of 192 HF subjects and found medication adherence <
40% to be associated with a three-fold higher incidence of rehospitalizaton for HF than
those whose adherence was > 80%. Both of these studies utilized pharmacy refill data
that may not accurately reflect patient-level adherence, and they did not establish a link to
causes of non-adherence.
Definition of cut point for adherence. There is some disparity in defining the cut point
for “adherent” versus “non-adherent”. Pharmaceutical trials have generally defined taking
80% of study medication as “adherent”, although the rationale for this cutoff is not well

defined (Osterberg & Blaschke, 200S). Non-adherence is usually thought of as missing
medication doses, however it may manifest in various ways, including underdosing,
overdosing, self-imposed drug holidays, and taking medication that is not prescribed—all
by the same patient (van der Wal & Jaarsma, 2008). In persons with HF, a minimum
medication adherence of 88% has been shown to predict improved event-free survival,
and a recent trial found all-cause mortality to be associated with <80% adherence to HF
medications (Fitzgerald et al., 2011; Wu, Moser, & De Jong, 2009). One study of
medication adherence and Cl in veterans with HF found poor adherence to medication
(78%) in the overall study cohort; and that adherence significantly worsened (73%, p =.
017) in those subjects with mild Cl (Hawkins, 2012).
Measurement of medication adherence. Currently, there is no gold standard used to
measure medication adherence. Methods of measuring medication adherence may be
described as direct or indirect. Direct methods, which include directly observed therapy
and detecting levels of the drug or its metabolite in the serum or the urine, are not
practical for routine clinical use (Ho, Bryson & Rumsfeld, 2009; Osterberg & Blaschke,
2005). Indirect methods include asking the patient about adherence, collecting patient
questionnaires or diaries, assessing clinical response, performing pill counts, ascertaining
rates of refilled prescriptions, and using electronic medication monitors (Lee, 2007;
Osterberg & Blaschke, 2005). Recent clinical trials have used electronic devices, such as
the Medication Event Monitoring System (MEMS), which register the date and time
when caps of medication bottles are removed (Wu, Moser, Chung & Lennie 2008). Such
devices have been shown to be valid instruments in measuring adherence of one or two
medications in research settings, but are impractical to use when measuring adherence to
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the multiple medications prescribed in routine care. Pill counts are relatively easy to
perform for any amount of medications, have been correlated in accuracy to electronic
monitors, and have been frequently used in randomized controlled clinical trials (Lee,
2007; Smith, Hankins, Hodson & George, 2010).
Interventions to improve adherence
Interventions have been tested to improve medication adherence in persons with
HF that largely focused on the healthcare system and providers. In one study of 314 lowincome patients with HF, subjects were assigned to usual care or a pharmacist-led
intervention for nine months; with a three-month follow up. Adherence improved in the
interventional group (78.8% vs. 67.9% in the usual care group) but this effect disappeared
once the intervention ceased (Murray et al., 2007). A systematic review of 79 randomized
controlled trials confirmed most interventions to improve medication adherence in
persons with HF did not have a large or sustained effect. The interventions that did have
an effect were complex and required involvement of multiple disciplines (Haynes,
Ackloo, Sahota, McDonald & Yao, 2008). Thus, it is not surprising that attention has
turned to examining patient-related factors for designing interventions to improve
adherence.
Patient-related factors and medication adherence in HF. HF usually occurs later in
life in persons with multiple other chronic diseases such as diabetes, coronary artery
disease, and depression (Lindenfeld, et al., 2010). These potentially frail patients are
confronted with potential polypharmacy and a fragmented medical care system that does
not offer reimbursement incentives to the healthcare provider for careful medication
reconciliation (Cutler & Everett, 2010).

Moser and Watkins (2008) point out the normative model in American healthcare
is the delivery of care on an acute, episodic basis. However, HF is a chronic disease, and
daily attention, or adherence, to multiple factors such as taking medications is needed to
maintain stability. The patient in the home must manage this ongoing process of selfcare. Self-care occurs as a result of a series of decisions made by patients, and thus
interventions to improve self-care may fail if little is known about the factors affecting
decision-making. The presence of Cl and/or poor HL may influence decision-making,
but this has not been well studied in veterans with HF.
Cognitive Impairment in HF
For the purposes of this study Cl may be defined as ranging from mild to severe
(dementia), manifesting as problems with memory, attention, learning, recall, motor
speed, reaction times, and executive functioning (Sauve, et al. 2009). Cl has been shown
to be a frequent condition in patients with HF, far above what is to be expected with
normal aging. A population-based study of 1075 persons in Italy found the risk of Cl
was 1.96-fold greater in those with HF (Cacciatore et al. 1998). A literature review of 22
studies from 1966 to 2006 compared pooled data from 2937 HF patients with 14,848
controls and concluded the odds ratio of HF patients having Cl to be 1.62 (Vogels,
Scheltens, Schroeder-Tanka & Weinstein, 2007). Another literature review of Cl in HF
found the prevalence of Cl ranged from 30-80% (Bennett & Sauve, 2003). A third review
of the literature from 2002-2007 examined 97 longitudinal studies and found the
prevalence of Cl in HF to be 25% to 50% (Pressler, 2008). This wide variance in
prevalence is probably due to the small select samples of very ill hospitalized patients
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included in the reviews. Thus these results may not be readily generalized to the
outpatient HF population. In addition, instruments used to measure Cl varied widely.
More recently, cognition has been studied in outpatients with HF using
sophisticated neuropsychogical instruments. One study tested of 414 participants (249
HF, 63 healthy, and 102 medical participants, i.e. those with conditions other than HF);
those with HF were found to have 24% more cognitive deficits than the controls. The
domains affected were primarily memory, psychomotor speed and executive functioning
(Pressler, Subramanian & Kareken, 2010). Another study compared 50 outpatients with
HF compared to age-matched controls in the community. All subjects completed
neuropsychological testing, and those with HF were found to have a four-fold risk for Cl
compared to controls (Sauve et al., 2009). None of these studies have evaluated the
association of poor HL or medication adherence in persons with HF and Cl.
Causal factors for Cl in HF. It is unknown if the increased occurrence of Cl with HF is
due to a direct causal association, or if both conditions are associated with certain patient
demographics such as advanced age and co-morbid disease states including diabetes,
anemia, sleep apnea, or stroke (U.S. National Library of Medicine, 2012). Previous
studies have suggested that low cardiac output, as well as variations in blood pressure are
associated with Cl, particularly in patients with ischemic cardiomyopathy (Kennelly,
Lawlor & Kenny, 2009; Woo, Kumar, Macey, Fonarow & Harper, 2009). Depression is
prevalent in persons with HF and is associated with both Cl and with poorer overall
outcomes (Hawkins et al. 2012, Rutledge, Reis, Linke & Greenberg, 2006). Prior
literature has also focused on the association of Cl with biomarkers for disease severity,
including increased B-type natriuretic peptide (BNP), serum creatinine, and glycated
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hemoglobin, as well as derangements in thyroid function, serum vitamin B12, and
thiamine levels (Lindenfeld et al., 2010).
Health Literacy
As important as Cl may be in contributing to poor medication adherence and thus,
poor outcomes, it is only one of many factors. A related, yet separate concept is poor
health literacy (HL), which may be described as an individual’s capacity to obtain and
process basic health information and negotiate the healthcare system well enough to
obtain necessary services and make appropriate health decisions (Nielsen-Bohlman,
Panzer, & Kindig, 2004). Health literacy is not simply a problem of reading fluency and
vocabulary (and thus is not dependent upon educational level), but instead is affected by
multiple factors such as the complexity of the information presented, and the patient’s
contextual knowledge, prior experience, and cognitive and functional abilities
(Evangelista, et al. 2010; Nielsen-Bohlman, Panzer, & Kindig, 2004; Moser and Watkins
2008). Numeracy skills, a subset of HL, are less discussed in the literature, yet are critical
to managing such common tasks as taking medication. For example, Davis et al. (2006)
found 70 % of patients with poor HL could correctly state the instructions on a
medication label, yet only 34% could actually demonstrate the number of pills to be
taken.
HL is usually categorized in three to five ordinal levels e.g. “below basic” (no
more than simple, concrete literacy skills), “basic” (simple and everyday literacy skills),
“intermediate” (moderately challenging literacy skills) and “proficient” (complex and
challenging literacy skills). Multiple articles cite the extremely high incidence of poor HL
in America; and usually reference the seminal National Assessment of Adult Literacy

(NAAL) study, which published data in 2003 showing only 13% of Americans possess
HL at the proficient level (National Center for Educational Statistics, 2012).
Disproportionately high levels of poor HL were found in vulnerable populations
including racial and ethnic minorities, the frail elderly, and those with low incomes
lacking health insurance.
Health literacy, Cl and outcomes. Healthcare providers remain largely oblivious of the
fact that the majority of their patients may have difficulty reading and understanding
healthcare information, and continue to provide their patients with written prescription
labels, consent forms, test preparation instructions, test results, health questionnaires, and
the like. Patients with low literacy are likely to feel anxious and ashamed about
communicating with the provider, and also may not tell anyone that they do not
understand basic health concepts (Parikh, Parker, Nurss, Baker & Williams, 1996). Poor
HL has been associated with poor outcomes such as non-adherence to treatment plans,
poor self-care behaviors, poorer physical and mental health, increased risk of
hospitalization, and increased mortality (Wolf, Gazmararian, & Baker, 2005). The effect
of HL on medication adherence in patients with cardiovascular disease in a large health
maintenance organization revealed patients with inadequate HL were at increased risk for
poor adherence (odds ratio: 1.37; 95% Cl 1.08 to 1.74) compared to those with adequate
HL. However, this rinding did not achieve statistical significance once adjustments were
made for age, race, gender, education and regimen complexity, suggesting another factor
may influence adherence (Keller, Wright & Pace, 2008). A study of 492 community
dwelling adults with hypertension found that Cl greatly reduced the influence of age,
education and race on HL scores (Levinthal, Morrow, Tu, Wu, & Murray, 2008).

However, this study enrolled primarily African-American females, and thus may not be
generalizable to the VA population of primarily Caucasian males. There is only one
interventional study evaluating improving medication adherence in HF by addressing HL;
314 low-income patients were randomized to usual care versus an intervention that
included face-to-face support with a pharmacist and materials designed for patients with
low health literacy. The interventional arm did show increased adherence, however, this
decreased back to baseline once the intervention ceased (Murray, et al. 2007). In
addition, only five medications were used in this study, which does not reflect the
polypharmacy often found in clinical practice (Hawkins et al., 2012).
Health literacy and veterans with HF. In America, low health literacy is a prevalent
and clinically under-recognized problem that directly impacts patient’s self care skills,
including medication management, and up to 57% of patients with HF may have poor HL
(Evangelista et al., 2010; Moser & Watkins, 2008; Morrow, 2006). One study conducted
in four VA medical facilities assessed HL in 1,786 veterans. This study showed veterans
actually had a lower prevalence of poor HL than what has been reported in the civilian
population; specifically only 8.3% had inadequate and 11.8% had marginal skills (Griffin
et al., 2010). There are no studies reporting the prevalence of poor HL in the veteran
population with HF.
Cl and HL in persons with HF. Memory and verbal fluency are decreased in patients
with Cl (Hawkins et al. 2012; Pressler, Subramanian & Kareken, 2010; & Sauve et al.
2009). Yet, both are needed to negotiate a HF patient’s complex medication regimen that
often requires thoughtful action based on evaluation of daily vital signs. Memory and
verbal fluency have also been found to be associated with poor HL, after controlling for
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mild Cl (Federman, Sano, Wolf, Siu & Halm 2009). Thus, interventions to improve
adherence in patients with low HL should also reduce demands on cognitive abilities. The
commonly accepted view that utilizing simple language and a series of illustrations for
health information will not help low-literacy patients if the pictures must be mentally
integrated to be understood (Morrow, et al. 2006).
Summary
HF is an epidemic threatening to overwhelm American healthcare. Poor
medication adherence leads to poor outcomes as evidenced by the excessive admissionreadmission cycle for HF. This is particularly important to the VA, the largest managed
healthcare system in the U.S. It is becoming increasingly clear that traditional models of
patient education to improve adherence are failing. Novel interventions, targeted to
improve adherence, and therefore, outcomes, by addressing underlying problems with Cl
and poor HL are needed. This literature review demonstrates the paucity of research in
veterans with HF about the effect of Cl and HL on medication adherence. A gap exists in
the current knowledge, as nothing has been documented about the prevalence of poor HL
in veterans with HF, or the relationship between Cl and HL on interventions designed to
improve medication adherence in this population.
Significance of Dissertation Research to Advancement of Nursing Knowledge
Unfortunately, there remains a lack of awareness on the part of healthcare
providers regarding the negative effects of poor HL and Cl on adherence and outcomes in
their patients with HF. There is also a paucity of data on how to address these problems
in actual clinical practice. Most interventions attempting to increase adherence have

focused on the healthcare system or the provider. In addition interventions have been
tested in populations stratified by illness, e. g. HF, coronary disease or hypertension,
rather than the unaddressed but underlying patient-related factors such as Cl and poor
HL. Knowledge about the mediating effect of HL on an intervention targeted to improve
MA in veterans with HF and Cl will help inform the design and implementation of future
interventions. Improved medication adherence will improve outcomes and decrease
healthcare costs.
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Chapter 3: Methods
Research Aims
The specific aims of the study were to:
Aim 1. Describe level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and
other key variables (including the intervention) had upon medication adherence in
cognitively impaired veteran outpatients with HF based on prior data from an
interventional study testing a pictorial medication sheet and alarmed pillbox to improve
medication adherence.
Research Design
The study was a retrospective, correlational, cross-sectional design using
secondary analysis of data from the completed TARGET pilot study. Selected clinical
and demographic variables, and reading HL and numeracy HL scores were retrieved from
the participant’s medical records. The TARGET study did not include information on
HL, yet reading HL and numeracy HL scores were available from the participant’s
medical records. Thus this design was selected to estimate the causal relationships
between reading HL and numeracy HL (included in existing outpatient medical records),
the intervention, other key variables, and medication adherence in a sample of cognitively
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impaired outpatient veterans with HF who participated in an interventional pilot study
testing a pictorial medication sheet and alarmed pill box to improve medication
adherence.
Participant characteristics
Setting. All study procedures were conducted at a large metropolitan Veteran’s
Administration facility, which serves an urban population of 246,000 veterans in southern
California.
Inclusion and exclusion criteria. All subjects in the pilot study were 18 years old or
older, had an established clinical diagnosis of HF, and screened positive for Cl using the
Saint Louis University Mental Status (SLUMS) exam (Tariq, Tumosa, Chibnall, Perry &
Morley, 2006). In order to participate in testing the pictorial medication sheet and
alarmed pillbox, participants were required to speak and read English, follow simple
directions, be able to see, and have the manual dexterity to take their own medications.
Thus persons with severe functional limitations, acutely decompensated HF, dementia
requiring a caregiver, or severe mental illness, such as active schizophrenia, were
excluded. Subjects were also excluded if they had a life expectancy of less than 6 months.
Sampling Procedures
Sampling method. The sample included subjects (n=40) from the TARGET pilot study.
These subjects were recruited as a convenience sample from the investigator’s outpatient
HF clinic.
Sample size and power analysis. The TARGET study was designed as a pilot study to
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test feasibility and effectiveness of the intervention. Thus, no power analysis was
conducted.
Data Collection Procedures
Data was retrospectively collected from the TARGET database and the electronic
medical record, and entered into an Excel spreadsheet on the investigator’s secure,
password-protected computer. Subject ID numbers were assigned sequentially, and all
data was de-identified. A master subject/linkage log was retained in a separate locked
research file in the investigator’s office. Any pen-and-paper files related to the study, as
well as IRB documents, were maintained in a separate, locked research file in the
investigator’s office.
Human Subjects Considerations
Prior to any data collection or analysis permission to conduct the study was
obtained from both the VA Loma Linda Healthcare System’s IRB and the University of
San Diego’s IRB. As this de-identified, secondary data, no consent will be obtained from
the subject.
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Measures
Table 1
Variable

Source

Validity/Reliability

Type and Level of
Data

Medication
Adherence

TARGET study
30-day pill counts

Calculated Change
Score (Lee, 2007)

Percent: 100%
indicated all pills taken
correctly

Health Literacy

S-TOFHLA*

Published validity
and reliability
widely used in
clinical practice
(Bass, Wilson, &
Griffith, 2003).

Score 0-36 reading

Continuous, ordinal,

Clinical: EF% z,
selected laboratory
values3, SBF4,
NYHA class5,
etiology of HF, co
morbidities

Clinic chart and
data from
TARGET study
database

N/A

Demographic:
Age, gender,
ethnicity, race,
living
arrangements,
educational level

Clinic chart and
data from
TARGET study
database

N/A

comprehension
Score 0-50 on
numeracy subscale

and dichotomous

Continuous, ordinal,
and dichotomous

1Short Test of Functional Health Literacy for Adults
2 Ejection fraction
3 to reflect disease severity: serum creatinine, hemoglobin, B-type natriuretic peptide, and
glycated hemoglobin; to reflect those usually associated with cognitive impairment:
thyroid stimulating hormone and vitamin B-12
4 Systolic blood pressure
5New York Heart Association functional class for HF severity

The data on the dependent variable, medication adherence, was obtained for each
subject from the 30-day pill counts collected before and after the prior TARGET study
intervention. To capture both overtaking and undertaking medication, a change score was
determined for each prescribed medication by computing the absolute difference between
the number of pills taken versus the prescribed number over the 30-day period. The
change score values for each medication were summed for each individual subject,
divided by the total number of pills prescribed, subtracted from 1, and finally multiplied
by 100 to obtain an adherence score expressed as a percentage. Thus, a value of 100%
indicated all pills were taken correctly. A value of 85% meant that 15% of prescribed
pills were either not taken, or overtaken, or a combination of both. All currently
prescribed medications were included in the pill counts except medications taken on an
“as needed” (pm) basis, injectables, and inhaled medications. Over the counter
medications were not included.
Data related to health literacy was based on participant’s scores on the Short Test
of Functional Health Literacy for Adults (S-TOFHLA). This instrument was derived from
the longer Test of Functional Health Literacy for Adults (TOFHLA) that was designed to
assess basic reading and numerical tasks encountered by patients in a healthcare setting
(Parker, Baker, & Williams, 1995). The S-TOFHLA has been shown to be valid,
reliable, and easily administered in a busy clinical setting (Bass, Wilson, & Griffith,
2003). It is a timed (seven minute) reading comprehension test using the modified Cloze
procedure; the patient reads common medical instructions that have every 5th to 7th word
in a passage omitted and is asked to select a word from 4 multiple-choice options to fill in
the blank spaces (Bass, Wilson, & Griffith, 2003; Parker, Baker, & Williams, 1995). This

test has been administered to patients in the HF clinic as part of usual care since January
2011. In addition, there is a 17-item, timed (ten minute) subscale of the TOFHLA that
tests the ability of patients to comprehend medication prescription labels, results of blood
glucose tests, clinic appointment slips, and financial assistance for healthcare
information. The numeracy subscale is scored in a weighted manner according to the test
manual, to create a final score ranging from 0-50 (Parker, Baker, & Williams, 1995). The
numeracy subscale had been administered to all TARGET participants as part of routine
HF clinical care. All HL scores are recorded on HF clinic progress notes, which are
maintained in the electronic medical record. There is no evidence in the literature that
HL scores as assessed by S-TOFHLA change over time.
Statistical Analysis
Study data was entered into an Excel database, then transferred into the computer
program, Statistical Package for the Social Sciences v. 20 (SPSS) (IBM Corporation), for
analysis. A p-value of .05 or less was considered significant. Initially, frequency
distributions for each variable were examined for normal distribution characteristics.
Then descriptive and inferential statistical analysis were performed as appropriate.
Descriptive statistics including measures of central tendency and frequency were
employed to address study aim 1: Describe the level of reading HL and numeracy HL in
the study population. Study aim 2, that addressed the strength and direction of the
relationships between reading HL and numeracy HL and selected clinical and
demographic variables in the study population, was explored using bivariate correlational
tests appropriate to the level of measurement (e.g. Spearman’s rho for ordinal data and
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Pearson’s r for interval or ratio level data). To achieve aim 3: Determine the direct and
indirect effects that HL and other key variables (including the intervention) had upon
medication adherence in cognitively impaired veteran outpatients with HF based on prior
data from an interventional study testing a pictorial medication sheet and alarmed pillbox
to improve medication adherence, structural equation modeling (SEM) was utilized for
analysis. This analysis was performed using Mplus v.7 software (A/plus, 2012), in
consultation with a statistician experienced in SEM.
SEM was selected as the best method to estimate the causal relationships between
HL, the intervention, other key variables and medication adherence. SEM offers an ideal
method of analysis as models can be constructed to reduce measurement error and
accommodate the complexity of the factors and relationships being studied. In addition,
though not a panacea for problematic distributions or model misspecification, the
bootstrapping option in Afplus was considered to address the small sample size in the
study population (Meyers, Gamst & Guarino, 2006).
Strengths and Limitations of Methods
There are important limitations to this research design. The sample size was
small, drawn from a pilot feasibility study, and was selected as a convenience sample
from the investigator’s HF population of predominantly elderly Caucasian males veterans
from an urban southern California VA medical center. The VA system offers ready
access to prescription medication coverage. Therefore, the results may not be readily
generalized to other populations. There is the recognized difficulty in objectively
measuring actual medication adherence with the pill counting technique. There is no data

available to know if HL scores obtained from the S-TOFHLA instrument would change
over time.
Strengths of the design actually mirror some of the limitations. The study sample
is homogeneous, and all have ready access to prescription medication coverage.
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A BSTRACT

Oajzcnvzs: The study objectives were (a) to describe the prevalence and severity
of cognitive impairment (Cl) in an outpatient veteran population with heart
failure (HF), (b) to describe the cognitive dom ains affected in those subjects
found to have Cl, (c) to examine clinical and demographic variables th at may be
associated with Cl, and (d) to determine the relationship between Cl and
medication adherence (MA). We hypothesized th a t Cl is a prevalent condition in
veterans with HF and is associated with poorer MA. Adherence to therapy is
essential for successful outcomes. Cl m ay affect adherence; little is known about
Cl in veterans with HF or the effect of Cl on MA.
Mit h o d s : We enrolled 251 veteran outpatients with HF. Subjects were screened
for Cl; adherence was determ ined by pill counts. Subjects with Cl underwent
further neuropsychologic testing.
Ris u l t s : Unrecognized Cl was found in 58% of subjects. Verbal learning,

immediate memory, and delayed verbal memory were m ost impaired. Cl was
significantly associated with poorer MA. Variables associated with Cl included
age, African-American race, depression, use of alcohol, and nonparticipation in
pill count.
Conclusion ; Unrecognized Cl was prevalent and associated with poorer MA. We

propose routine screening for Cl in patients w ith HF.
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Heart failure (HF) is a prevalent, complex, and chronic
m edical condition th a t currently affects 5.8 million
people in th e U nited States, contributing significantly to
increased m ortality, morbidity, and healthcare expen
ditures, a n d decreased quality o f life.1*2 T he negative
im pact o f HF o n patien t outcom es and healthcare costs is

projected to escalate as th e Am erican population ages
and is o f particular im portance to th e Veterans Affairs
(VA) h e alth care system , th e largest integrated h e alth 
care system in th e U nited S ta te s .14O utpatient encoun
ters for HF in th e VA system have increased from 550,000
in 2002 to 900,000 in 2009 and represent not only the
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increasing num bers of veterans w ith HF but also the
increasing intensity of care these patients require.4
Large clinical trials have d em onstrated th e success
o f pharm acologic a n d lifestyle strategies in im proving
p a tie n t outcom es and have resulted in th e develop
m en t o f con sen su s guidelines.1 However, p atients w ith
HF ten d to b e older a n d to h av e m ultiple comorbidities,
and m ay find it difficult to follow th ese often com plex
regim ens, thereby losing th e benefits o f evidencebased care.4’s One particularly im p o rtan t m anifesta
tion o f poor HF outcom es is th e frequency of
adm issions. In th e VA system , 20% of patients w ith HF
are read m itted w ith in 30 days.4 N onadherence to
m edication h a s b e en show n to be responsible for th e
m ajority o f readm issions for HF in th e U nited States.5"
10 Of even m ore concern, a recent trial linked m edica
tion n o nadherence, defined as < 80% adherence to HF
m edications, to all-cause m ortality.11 T hus, identifica
tion a n d intervention for key factors contributing to
poor m edication adherence (MA) have becom e prim ary
goals for clinicians and healthcare policym akers.4
P harm aceutical trials have generally defined taking
80% o f study m edication as “adherent,'' although the
rationale for this cutoff is n o t well defined.12 In persons
w ith HF, a m inim um MA o f 88% has been show n to
predict im proved event-free survival.13 Populationbased studies have show n MA to be as low as 40% to
50%, highlighting th e im portance of focusing on
adherence to im prove p a tie n t outcom es.5,12"15
Adherence is a com plex issue and depends on m ultiple
p atient and healthcare-related factors. Nonadherence is
usually thought o f as m issing m edication doses;
however, it m ay m anifest in various ways, including
underdosing, overdosing, taking self-im posed drug holi
days, and taking m edication th a t is n o t prescribed—all by
th e sam e patient.16 The World Health Organization's
M ultidim ensional Adherence Model classifies predictors
of poor adherence into 5 broad dom ains: socioeconomic
status, type o f healthcare system , prescribed therapy,
condition being treated, and individual patient-related
factors.17 However, this m odel explained less th an 20%
o f poor adherence in patients w ith HF, em phasizing the
need to identify o th er contributors to nonadherence in
this population.11 One frequently overlooked factor th at
m ay influence all of these dom ains is the presence of
cognitive im pairm ent (Cl).
Cl m ay range from m ild to severe (dementia), m a n 
ifesting as problem s w ith m em ory, attention, learning,
recall, m o to r speed, reaction tim es, and higher level
orders of reasoning (executive function).19 It is clini
cally intuitive th a t im pairm ent in any o f th ese dom ains
w ould negatively affect p atien ts' abilities to correctly
take th e ir m edications, y et a ssessm en t for Cl rem ains
rare in clinical practice.20"22 Persons w ith HF have been
show n in re ce n t studies to have up to a 4-fold higher
risk o f developing Cl com pared w ith th e general pop
ulation, a n d th e overall prevalence o f Cl in o utpatients
w ith HF h a s been show n to be as high as 50%.19,23 A
lim itation o f previous studies exam ining Cl in HF is the
selective inclusion of persons w ith low left ventricular
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ejection fraction (LVEF), despite th e fact th a t > 50% of
HF adm issions in th e U nited States are for p atients
w ith preserved systolic function.1 In addition, these
studies h ave n o t exam ined th e direct relationship o f Cl
to MA in a selected population.
It is unknow n w h e th er the increased occurrence of
Cl w ith HF is due to a direct causal association or if b oth
conditions are associated w ith certain patien t dem o
graphics, such a s advanced age a n d comorbid disease
states, including diabetes, anem ia, sleep apnea, and
stroke.19,23 Previous studies suggest th a t low cardiac
ou tp u t and v ariations in blood pressure are associated
w ith Cl, particularly in p a tie n ts w ith ischem ic cardio
m yopathy.19,24,25 D epression is prevalent in persons
w ith HF a n d associated w ith b oth Cl and poorer overall
outcom es.15,26 Prior literatu re h a s also focused on the
association o f Cl w ith biom arkers for disease severity,
including increased B-type n atriuretic peptide, serum
creatinine, and glycated hem oglobin, as well as
d erangem ents in thyroid function, serum vitam in Bu ,
a n d thiam in e levels.27"29
The older A m erican veteran is a t risk for m any of
these com orbid illnesses. For exam ple, th e m ajority o f
veterans w ith HF h ave ischem ic h e art disease and
approxim ately one third have diabetes.4 In addition, the
effects o f post-traum atic stress disorder and substance
abuse in th e veteran population on HF outcom es are not
well understood. To date, th ere are no published studies
o n th e prevalence of Cl a n d its potential effect o n MA and
outcom es in th e outp atien t veteran population w ith HF.
T here are several advantages to conducting this
investigation in a veteran population. T he VA system
p resen ts a large a n d relatively controlled environm ent
o f m anaged care, a n d data collection is facilitated by
a w ell-established, com prehensive electronic m edical
record system . In addition, veterans have increased
access to care com pared w ith th e general population,
including assistance w ith transportation to clinic
appointm ents. M ost im portant, m edications are
provided from th e VA form ulary a t no cost or for a low
fixed co-pay. Yet despite th is seem ingly ideal system ,
HF outcom es rem ain problem atic as evidenced by the
excessively high readm ission rate.4
The objectives o f th is stu d y w ere (a) to describe the
prevalence and severity o f Cl in a n o u tpatient veteran
population w ith HF, (b) to describe th e cognitive
dom ains affected in th o se subjects found to have Cl, (c)
to exam ine clinical a n d dem ographic variables th a t
m ay be associated w ith Cl, a n d (d) to determ ine the
relationship betw een Cl a n d MA. W e hypothesized th a t
Cl is a p revalent condition in veterans w ith HF th a t is
associated w ith poorer MA.

M a ter ia ls a n d M eth o d s
This study w as designed a s a prospective observational
cohort stu d y a t a large m etropolitan V eterans
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A dm inistration facility, w hich serves an urban
p opulation o f 246,000 veterans in southern California.
T he institutional review board approved th e study, and
all subjects provided w ritten inform ed consent before
enrollm ent.

Study Population
Clinical providers and research coordinators screened
all eligible p a tie n ts for th e study w h o presented to th e
o u tp atien t HF a n d general m edical clinics a t a VA
m edical c en ter betw een Decem ber 2009 and March
2011. Patients w ere eligible for enrollm ent if th ey had
an established clinical diagnosis of HF. R ecruitm ent
w as n o t b ased o n specific lim its of LVEF. Persons w ith
a life expectancy o f less th a n 6 m o n th s o r docum ented
d em en tia requiring a caregiver w ere excluded from the
study. To participate in cognitive function testing,
p articipants w ere required to speak English, follow
sim ple directions, a n d be able to draw sim ple figures.
T hus, p a tie n ts w ith severe functional lim itations,
acutely decom pensated HF, o r severe m en tal illness,
such a s schizophrenia, w ere not included. No subjects
h a d know n Cl before enrollm ent into the study.

Procedures
At th e initial study visit, all subjects w ere screened for
Cl, depression, a n d propensity to adhere to their
prescribed m edication regim en. Selected clinical and
dem ographic variables w ere collected by direct patien t
interview u sin g sta n d a rd questions a n d m edical record
review. Subjects w ere asked to retu rn for a second and
th ird study visit bringing in th eir regularly prescribed
m edications for a d irect 30-day pill c ount to d eterm ine
MA. Subjects w ho initially screened positive for Cl w ere
invited back for a fourth study visit to undergo a n e u 
ropsychologic te s t battery. Screening, interviewing,
a n d d a ta collection w ere conducted by 2 research
coordinators u n d e r th e supervision of th e investiga
tors. T he stu d y flow sheet is presented in Figure 1.

Variables an d Measures
Screening fo r Cl
Subjects w ere screened for Cl using th e Saint Louis
University M ental Status (SLUMS) exam ination.30 The
SLUMS exam ination consists of a 30-point education
adjusted, clinician-adm inistered interview scale th a t
classifies p a tie n t im pairm ent a s none, mild, or
im p airm en t con sisten t w ith dem entia. Specifically,
SLUMS screening is considered positive for m ild Cl if
th e score is < 27 in a person w ith a high school diplom a
or < 2S in a p erso n w ho did n o t com plete high school.
SLUMS screening is considered positive for severe
im p airm en t c o n sisten t w ith dem entia if th e score is
< 21 for p ersons w ith a high school diplom a a n d < 20
for p ersons w ho did n o t com plete high school.
T he SLUMS exam ination contains 11 questions th a t
incorporate tasks correlating w ith specific cognitive
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Subjects who meet inclusion criteria ate enrolled

1. Subjects screened for cognitive impairment with SLUMS exam
2. Clinical/demographic variable collection

Cl Screen potlttve

Modified neuropsychological
battery

All subjects bring in medications for pill count

All subjects return for 30-day repeat pill count to determine
adherence

Figure 1 - Study flo w s h e e t (3, confidence interval;
SLUMS, S a in t Louis U niversity M ental Status.

dom ains. T hese include im m ediate recall a n d orien
tatio n (day o f w eek, year, a n d place); delayed recall
w ith interference (subjects are asked to rem em ber 5
objects and recall th em after 2 intervening questions);
n um eric calculation a n d registration (a 2-part m ath
story problem ); sem antic fluency (nam ing as m any
anim als a s possible w ithin 1 m inute); working m em ory
(reciting n u m b ers backw ard), visual spatial and exec
utive function (dock-draw ing test); visual spatial
function (recognizing geom etric figures); and contex
tual verbal m em ory (subject listens to a sh o rt story and
answ ers 4 questions a bout th e story's content).
T he SLUMS exam ination w as selected for o u r study
for several reasons. T he SLUMS exam ination contains
em pirically derived cutoff scores based on a stu d y of
702 p atien ts from a n u rban VA system w ith dem o
graphics sim ilar to o u r sam ple of predom inantly
elderly Caucasian m en.33 This validation stu d y indi
cated th a t th e SLUMS exam ination h a d high sensitivity
(98%-100%) a n d specifirity (98%-100%) for detecting the
p resence o f d em entia. In addition, th e SLUMS exam i
n ation w a s sh o w n to be m ore sensitive in detecting
m ild Cl th a n th e fam iliar Mini M ental Status Exam,
w ith sensitivity o f 93% versus 67% for patients w ith less
th a n high school education, a n d 94% versus 67% for
p a tie n ts w ith a high school diplom a or above.33*33 T he
SLUMS exam ination includes a dock-draw ing test,
w hich is especially sensitive in detecting im paired
executive function.34 Finally, th e SLUMS exam ination
is quick to adm inister, taking approxim ately 7 m inutes,
and m ay be conveniently dow nloaded a t no charge
from th e Internet.35
Neuropsychologic Testing
Our study w as designed to further te st those subjects w ho
screened positive for Cl to determ ine the cognitive
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dom ains m ost affected. To be tolerable for older subjects
w ith HF, a modified com prehensive battery of neuro
psychologic testing w as chosen th a t could be completed
in one 2-hour session. In addition to brevity o f adm inis
tration, tests w ere selected on the basis of (a) sensitivity to
th e presence o f Cl including dem entia, (b) available test
norm s w ith dem ographic adjustm ents, and (c) published
research establishing good psychom etric properties of
each in stru m e n t The dom ains tested included im m e
diate a n d delayed verbal m em ory, delayed nonverbal
m em ory, visuospatial/constructional ability, language,
verbal learning, attention, inform ation processing speed,
executive functioning, m otor dexterity, and premorbid
intellectual functioning. The specific tests included
Repeatable Battery of A ssessm ent of Neuropsychological
Status,36 Trail Making Tests,37 W echsler Test o f Adult
Reading,36 Grooved Pegboard Test,39-40 phonem ic and
sem antic verbal fluency tasks,41,43 and Similarities,
Matrix Reasoning, Letter Num ber Sequencing and Digit
Span subtests from the W echsler Adult Intelligence Scale,
4th edition.37,43 All exam inations were conducted and
scored by a single research coordinator trained in
psychom etric testing under the supervision of our
neuropsychologist investigator.
Screening for Depression
T he Geriatric D epression Scale (GDS) screens for
depression in th e elderly.44 It is a widely used selfre p o rt consisting of 30 sim ple yes/no questions su it
able for th e ill or th e m ildly cognitively im paired
person. T he GDS h a s a n acceptable reported internal
consistency o f .94 (Cronbach's alpha) a n d a split h alf
reliability o f .94.44,43 C utoff scores are as follows: 0 to 9
as norm al, 10 to 19 as m ildly depressed, and 20 to 30 as
severely depressed.

Demographic and Clinical Variables
Dem ographic a n d clinical variables th a t m ight predict
or influence th e finding o f Cl in th e study sam ple w ere
selected o n th e basis o f review o f relevant literature as
described in th e introduction. These d a ta w ere orga
nized into 5 categories: dem ographic, health-related,
HF-related, behavioral health-related, and clinicrelated variables. Dem ographic d a ta included age,
gender, ethnicity, living arrangem ents, em ploym ent,
educational level, a n d self-perceived financial distress.
H ealth-related variables included systolic blood p re s
sure, th e p resence o f selected com orbidities (diabetes,
hypertension, obstructive sleep apnea, stroke, and
atrial fibrillation) a n d selected laboratory values
(B-type natriuretic peptide, glycated hemoglobin,
seru m creatinine, thiam ine, vitam in B12, hem oglobin,
and thyroid stim ulating horm one levels). V enipunc
tu re and blood specim en processing w ere conducted as
p a rt o f routine m edical care a t th e VA’s clinical labo
ratory. HF-related variables included HF cause, HF
duration, a n d LVEF a s m easured by echocardiogram .
Behavioral h ealth -related variables included docu
m en ted histo ry of depression, depression as m easured
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by GDS, docum ented history o f post-traum atic stress
disorder, a n d self-reported u se o f tobacco, alcohol,
m arijuana, o r illicit substances. Clinic-related variables
included tre a tm e n t provided by th e specialized HF
clinic versus general m edical clinics, n u m b er of
prescribing providers, and n um ber of hospitalizations
in th e p a st year. T he n u m b er a n d type of prescribed
m edications w ere collected during th e pill counts on
th o se subjects w ho retu rn e d for pill counts.

Screening for Propensity to Adhere to
Medication
All subjects w ere screened for propensity to adhere
using d ie M edication A dherence Estim ator.46 This 3item in stru m e n t w as designed to estim ate a patien t’s
propensity to ad h ere to m edications prescribed for
chronic disease a n d w as validated in a large sam ple of
elderly p atien ts using p h arm acy claim s d a ta over a 9m o n th period.47 R espondents are scored as low,
m edium , o r high risk for nonadherence.
Medication Adherence
Subjects w ere asked to bring their regularly taken
prescription m edications to be counted a t th e beginning
o f th e study a n d again a t 1 m o n th to obtain a direct 30day pill count. T h e pill c ount included all prescribed
m edications, n o t only th o se for HF, to reflect overall pilltaking behavior. M edications tak en on a n as-needed
basis, injectables such a s insulin, and inhaled m edica
tions w ere excluded from th e pill c o u n t Two research
coordinators counted pills in th e clinic in th e presence of
th e subjects, b oth m anually a n d w ith a T oibal DRX 300
NTEP (Fulcrum Inc., Clifton, NJ) certified pharm acy scale.
An MA score for each subject w as com puted from
th e 30-day pill counts. To capture b oth overtaking and
u ndertaking m edication, a ‘‘d elta’ w as determ ined for
each m edication by com puting th e absolute difference
betw een th e n u m b er o f pills taken a n d th e n um ber
prescribed over th e 30-day period. T he delta values for
each m edication w ere su m m ed for each individual
subject, divided by th e total n u m b er of pills prescribed,
subtracted from 1, a n d finally m ultiplied by 100 to
obtain an adherence score expressed as a percentage.
T hus, a value o f 100% indicated th a t all pills w ere taken
correctly. A value o f 85% m e a n t th a t 15% o f prescribed
pills w ere n o t taken, overtaken, or a com bination of
both. Expressed m athem atically, if th e jth p atient w as
prescribed pjt a n d consum ed cjt o f m edication i, th en
MA can be com puted for each jth p a tie n t

S ta tis tic a l A n a ly s is
Data analysis w as conducted using th e Statistical
Package for th e Social Sciences version 19 (SPSS Inc,
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Chicago, IL).48 P values of .05 or less w ere deem ed
significant. Descriptive sum m aries included m eans
a n d sta n d ard deviations for continuous variables and
c ounts a n d percentages for categorical variables. To
facilitate m ak in g sem antically interpretable com pari
so n s o f relative effect sizes across variables, neuro
psychologic te st scores, age, and LVEF variables w ere
transform ed into z scores by subtracting th e sam ple
m e a n from th e raw score a n d dividing th e difference by
th e sam ple sta n d ard deviation.
To achieve study objective “a," SLUMS scores w ere
obtained for each subject. The SLUMS scores calculate
Cl a s a 3-item ordinal scale (none, m ild, a n d im pair
m en t c o n sisten t w ith dem entia). For th e initial anal
ysis, subjects w ere identified as “no Cl* or “CL” For
fu rth er analysis, subjects w ith Cl w ere fu rth er grouped
in to 2 categories', m ild o t severe (im pairm ent consis
te n t w ith dem entia).
To achieve stu d y objective "b,” neuropsychologic
te st scores w ere standardized on th e basis of the indi
vidual te s t m an u a l or published dem ographically
adjusted te st norm s.49
To achieve study objective “c,” unadjusted associa
tions am ong clinical, dem ographic, and Cl variables
w ere a ssessed using S pearm an's rho for ordinal vari
ables o r Pearson’s tests for interval or ratio variables.
Predictors o f Cl w ere com puted from univariate
generalized lin ear regressions w ith a n ordinal m ulti
nom ial link a n d robust sta n d ard errors. For categorical
predictors (eg, race), effect sizes o n Cl w ere reported as
sim ple odds ratios. For continuous predictors (eg, age),
effect sizes on Cl w ere reported as odds ratios repre
se n tin g th e change in th e likelihood o f increasing Cl by
1 level (eg, n o n e to m ild im pairm ent, or m ild to severe
im pairm ent) for a change in 1 stan d ard deviation of the
predictor variable.
To achieve stu d y objective “d,“ u nadjusted and
adjusted associations betw een Cl and MA w ere
estim ated using generalized linear regression. Esti
m ate s w ere adjusted for age, race (African-American),
ethnicity (Hispanic), living arrangem ents (living alone),
n u m b er o f hospitalizations in the prior year, and
tobacco use. T hese adju stm en t variables w ere selected
to contain dem ographic a n d health-related factors
identified by a literature review a n d th e predictor's
perform ance o n this dataset to explain MA or Cl.

Resu lts
A total o f 251 subjects w ere recruited. The ethnically
m ixed population served by th e hospital (predom i
n antly 60% Caucasian, 9% African-American, and 8%
Hispanic) w as fairly w ell reflected in th e study sam ple
o f 72% Caucasian, 13.6% African-American, a n d 9.6%
H ispanic subjects. Subjects w ere predom inantly m ale
(99%), w ith a m ean age o f 66 years (standard deviation
± 9.8; range, 33-93 years). Baseline characteristics for
th e cohort are show n in Table 1.
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W e found a high prevalence of unrecognized Cl in
o ur cohort; 58% (144/2S0) o f p atients h a d Cl based on
th e SLUMS screening test; 41.6% of these h a d m ild Cl
a n d 16% h a d severe im pairm ent consistent w ith
d em entia (Table 2). All subjects w h o screened positive
for Cl d uring th e initial study visit w ere invited back for
fu rth er neuropsychologic testing. Despite vigorous
efforts by th e stu d y team , only 61% (89/144) actually
retu rn e d for fu rth er testing. Of th e cognitive dom ains
tested, verbal learning, im m ediate m em ory, a n d
delayed verbal m em ory w ere found to be th e m ost
im paired based on a z score o f < -1 .5 . Results of neuropsychologic te s ts are show n in Table 3.
T able 4 p resen ts th e results o f bivariate analyses
b etw een study variables a n d CL G w as positively
associated w ith age, African-Am erican race, depres
sion a s m easu red by th e GDS, and use of alcohol, in
addition, Cl w as associated w ith not returning for pill
counts; how ever, th is is n o t a variable th a t could easily
be identified in a clinical setting.
Although all study subjects (both those w ith and
w ithout Cl) initially agreed to re tu rn for th e pill count,
only 67% (168/250) o f th e enrolled subjects did so.
Overall adh eren ce in th e cohort o f p atients w ho
participated in th e pill count w as poor; subjects w ith no
Cl h a d adh eren ce o f 78%, th o se w ith m ild Cl h a d
adherence o f 70%, a n d those w ith severe Cl had
ad herence o f 73%. Specifically, com pared w ith no Cl,
MA significantly w orsened b y 8 percentage points (78%
to 70%, P = .017) for p a tie n ts w ith m ild Cl, b u t did n o t
continue to w orsen for p atien ts w ith severe Cl in th e
d em en tia range. Sim ilar findings w ere found betw een
u n a d ju ste d a n d adjusted estim ates (Table 5).
O ur regression analyses revealed a robust associa
tion b etw een th e presence o f Cl a n d MA. Am ong th e
study variables listed in Table 4, only Cl w as found to
h ave a statistically significant association w ith MA. W e
also found b oth overtaking a n d undertaking prescribed
m edications to be com m on in our study sam ple;
however, no statistically significant p attern s or trends
w ere found.
Results from th e A dherence Estim ator survey
revealed th e m ajority o f subjects intended to take
th eir m edications. Specifically, 52.2% (116/214) scored
a t low risk, 35% (75/214) scored a t m edium risk, a n d
10% (23/214) scored a t high risk for potential n o n 
adherence. However, th ese scores w ere n o t signifi
cantly correlated w ith actual MA found in th e study
population.

D is c u s s io n
Our stu d y dem o n strated 2 im p o rtan t findings: a high
prevalence o f previously unrecognized Cl in veterans
w ith HF a n d th e association o f Cl w ith poorer MA.
These findings have vital im plications for the
successful tre a tm e n t o f HF in th e veteran population.

33
HEART k I U N C

Demographic v e rifie s
Age (y) mean ± SD
Male gender (n - 251)
Race/ethnidty (n - 250)
Caucasian
African-American
Hispanic
Employment (n - 248)
Employed
On disability
Retired
Unemployed
Living arrangements (n - 249)
Live alone
Live with spouse/partner
Live with children
Other
Education (n « 248)
Less than high school
High school diploma
SomecoQsgp
College degree or above
Self-perceived financial status
(n - 221)
Doe* not affect ability to care
for health
Affects ability to care for
health
Health-related variables
Diabetes (n - 251)
Coronary artery disease
(n - 251)
Hypertension ( n + 251)
Obstructive shiepapnea
(n - 251)
History of stroke (n - 251)
History of atrial fibrillation
(n -2 5 1 )
Systolic blood pressure mean *
SD (mm Hg)
Thiamine level, mean * SD
(nmol/L)
Vitamin Bna level, mean * SD
(pg'mL)
Hemoglobin level, m ean * SD

WW

Serum creatinine level, mean *
SD (m^dL)
Thyroid-stimulating hormone,
mean * SD (uIU/mL)
BNP * SD (range) (pg/mL)
HgbAic ± SD (range) (%)
HF-related variables
HF duration (n - 248)

66,4 *9.8
247(98.4%)
180 (72.0%)
34(13.6%)
24(9.6%)
. 25(10.1%,
61(24.6%)
151(60,9%)
11 (4.4%)
68(27.3%)
142 (57.0%)
17 (6.8%)
22 (8.8%)
25 (10.1%)
60 (24.2%) .
103(41.5%)
60(24.2%)
111(50.2%)
110 (49.8%)

134(53.4%)
160(63.7%)
193(76.9%)
68(27.1%)
26(10.4%)
82(32.7%)
125.8 * 19.67
169 * 95.60
556.81 298.26
13.6 ±2.19
159 .* 1.84

History of depression (h + 298)
GDS score, mean * SD*
PTSD (n - 251)
Tobacco use (n - 248)
Never smoked
Former smoker
Currant smoker
Alcohol use (n -2 5 1 )
Never
Former use
Current use 5 3 drinks/wk
Currant use >3 drinks/wk
Marijuana use (n + 248)
Never
Pasture
Current use
Other illicit substance use
(n -2 4 8 )
Never
Pasture
Cunentuse
Clinic-related variables
:
Treated in specialised HF clinic
(n-251)
NO. of prescribing providers,
mean * SD (range)
No. of hospitalizations in past
year, mean * SD (range)
HF medications (n - 168)
ACE inhibitor
Angiotensin receptor Mocker
Beta-blocker
Diuretic
Digordn
Isosoibide/hydralazine
Aldosterone antagonist
No. of prescriptions (n -168),
mean * SD (range)

76(303%)
13,3*3.80
47(18.7%)
47 (19.0%)
154(62.1%)
47(19.0%,
80(31.9%)

8S0Sii%)
29(11.6%)
156(62.9%)
78(31.5%)
14(5.6%)
190(76.6%)
57(23.0%)

H*%)
143 (57.0%)
5.4*2.4(1-13)
.58*112(0-7)
128(76%)
52(31%)
192(114%)
176(105%)*
47 (W%)
31(19%)
38(23%)
7.83 * 3.06 (1-17)

_ \CE, angiotensin-converting enzyme, BNP. »-typs nStri_ rretic peptide; GDS, Geriatric Depression Scale; HF, heartL
_ failure; HgbAic, glycated hemoglobin; LVEP, left ventricular,
_ Section fraction; PTSD, post-traumatic stress disorder; SD,
_ itandard deviation.
- 'Diagnosis based on d u e t review.
. jScore O-9 - normal,10-19 - mild depression, 20-30 -

- revere depression.
-I May reflect combination diuretic th erapy.-------------------

274.7 * 497 (2-5000)
6.8 ±1.5 (4.2-15.4)
o f ( <>cj n ! i v i ■ j n 111
' 111 v> -i ■ .!

22 (8.8%)

>Sy

104(41.8%)
123 {492%)

HF cause* (n - 238)
Ischemic
Nonischemic
LVEF(n-249)
>40%
<40%
LVEF, mean * SD

I - I I

2.99 * 4.39

<ly

l-Sy
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131(55%)
107(45%)
85(34.1%)
164(65.9%)
37.5 * 16.90
(continued)

\ h oi.

'Mi,

Hone

f

Mild impabrment
Severe impairment (dementia)
SLUMS score, mean * SD (range)
SLUMS administra tion time in
minutes, mean * SD (range)

t i t (414X1
104(41.6%)
40(16.0%)
24.39 * 4,0 (12-30)
7.1*1.4(4-15)

- 3, cognitive impairment; SLUMS, Saint Louis Univerrit)
-Mental Status; SD, standard, deviation . 11 ■■
——
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R e s u lts ol in -in o p s y c iio lo ^ic te s tin i;'

Estimate of premoiMd IQ
Attention
Information processing speed
Language
Visuospatial abilities
Verbal learning
Delayed verbal memory
Delayed nonverbal memory
Executive functioning
Motor dexterity

WTAR
WAIS-IV digit span
WAIS-IV tetter-number sequencing
a ge< 69y
Trails A
RBANS coding
RBANS picture naming
Animate
RBANS semantic fluency
RBANS figure copy
RBANS line orientation
WAIS-IV matrix reasoning
RBANS list teaming
RBANS story memory
RBANS list recall
RBANS flat recall recognition
RBANS story recall
RBANS recall figure
COWAT
Trails B
WAIS-IV similarities
Grooved pegboard Dominant hand
Grooved pegboard nondominant hand

69
84
54

9.867(81-119)
.88 (-1 6 7 to 10)
.68 (-3.00 to 133)

89
89
89
88
89
89
89
84
89
89
89
89
89
89
88
88
84
85
83

.99 (-3.80 to 1.40)
.87 (-3.81 to 4.3)
1.34 (-9.33 to .90)
1.17 (-3,20 to 2.10)
£8 (-2.85 to 1.74)
1.53 (-6.00 to 1.35)
.85 (-2,28 to 1.29)
.98 (-133 to 2.00)
.96 (-4.92 to .96)
1.08 (-3.92 to 1.0)
.91 (-186 to .95)
1.84 (-7.67 to .67)
1.21 (-4.14 to .91)
1.04 (-3.4 to 1.97)
.90 (-3.0 to 1.30)
1.04 ( - I S to 10)
.70 (-2.0 to 1.33)
1.08 (-3.60 to 1.40)
1.12 (-3.5 to 1.80)

98.71
-.60
-.56
-X
-1.196
1257
-.57
-.8645
-.6670
.1030
-.20
-1.904*
-1.589*
-1145
-1,798*
-1840*
-.3637
-.74
-.73
-.17
-.70
-.91

. 30WAT, Controlled Oral Word Auociadon Test; IQ, inteffigence quotient; R8ANS, Repeatable Battery of Assessment of Neu- _
_ropsychologicel status; SD, standard deviation; WAIS-IV, wechsler Adult Inteliigenoe Scale, 4th edltiwvWlWVSf'eehslarTosi.
. i f AdultReedlng.
<-1.5 SD considered impaired. ■■■■
. 1AD standardixed sco rn are presented in x scores with the exception of estimate of premorttid IQ (Wechsler Test of Adull_
L
J t eadintf, whieh la presented In a standard score with a mean of 100 and 6D of 15.------------------ *— ----- .-------

Previously unrecognized Cl w as found in 58% of our
sam p le o f veteran s w ith HF. This prevalence, although
unexpectedly high, is consistent w ith o th er studies
conducted in n o nveteran outpatients w ith HF.19 23 in
o u r v e te ran population, w e found th e expected positive
association o f Cl w ith age. O ther significant associa
tions included African-Am erican race, use of alcohol,
depression as m easured by th e GDS, and increased
likelihood of n o t returning for th e pill count. Com or
bidities show n in prior literature to be associated w ith
Cl in HF, including abnorm alities in blood pressure, low
LVEF, o r ischem ic cause o f HF, w ere not found to be
statistically significant in our study sam ple. This
discrepancy m ay be explained by th e heterogeneous
population in our stu d y th a t included outpatients w ith
all-cause HF com pared w ith prior studies th a t m ay
have preferentially evaluated sicker patients.
T he cognitively im paired subjects w ho com pleted
fu rth er neuropsychologic testin g dem onstrated
significant deficits in th e dom ains o f verbal learning,
im m ediate m em ory, a n d delayed verbal m em ory. This
effectively m ea n s th a t m any cognitively im paired
p a tie n ts will n o t understan d , or will forget, w h at th e
provider h a s ju s t instru cted th e m to do soon after
leaving th e clinic environm ent. By extension, in te r
ventions th a t rely on traditional m odels o f patien t
education to im prove adherence w ould likely fail in
th is p a tie n t group. The m ajority of subjects w ho failed

to re tu rn for testin g sim ply did n o t re tu rn m ultiple
telephone m essages or respond to w ritten rem inders to
do so. It is unknow n w h e th er this reflects a n o th er
aspect o f poor ad herence associated w ith Cl or w h eth er
o th er factors, such as n o t w anting to spend th e tim e or
n o t clearly u n d erstan d in g w h a t w as expected o f them ,
contributed to th e low rate o f return. This intriguing
discovery deserves additional investigation in future
studies because o f th e potential im pact on actual
ad herence estim ates.
C onsistent w ith our original hypothesis, Cl w as the
only factor studied th a t w as found to be associated
w ith poorer MA in o u r stu d y population. The im pact on
adherence seem ed to begin w ith m ild Cl a n d did n o t
continue to w orsen for pa tie n ts w ith severe Cl in the
d em en tia range. This is particularly im portant to clin
ical practice because th e presence o f m ild Cl is easily
m issed; th e p atient, w ho m ay deny needing any
assistance w ith m edication adm inistration, often
hides m em ory loss.*-10 W e are uncertain as to w hy th e
m ore severely affected subjects did n o t have w orsened
MA. It is possible th ese subjects w ere actually receiving
assistance from fam ily m em bers or others; however,
living arran g em en ts (alone o r w ith others) w ere n o t
significantly associated w ith MA in o u r study sam ple.
Finally, it is u n know n w h e th er subjects w ere n o n 
a d h ere n t before becom ing cognitively im paired or
w h e th er prior n onadherence actually contributed to Cl.

OR
Demographic variables
Age (z score)
1.41
African-American race
3.22
2.17
Hispanic race
Uves alone
f i ll
Health-related variables
Diabetes
.960
Thiamine (z score)
1.10
TSH (z score)
1.21
Vitamin B« (z score)
1.19
Hemoglobin (z score)
.735
1.35
Creatinine (z score)
HF-related variables
Duration of HF
1-5 y
154
6-10 y
1.02
>10 y
.970
Cause of HF
ischemic v* nonischemic
.894
LVEF(z score)
1.16
Systolic BP (z score)
1.22
Behavioral health-related variables
Geriatric Depression Scale
1.38
fz score)
Tobacco use
Never or prior
.546
Current smoker
.436
Alcohol use
Never
134
Former use
1.67
. Current use 3 drinks/wk
396
Currentuse 4*7 drinksfwh 1.62
Current use >B drinks/wk 1.62
Marijuana use
Never or prior
.608
Current use
1.10
Clinic-related variables
HF clinic patient
.639
Did not return for pill count 2.33
Hospitalized in past year
1.08

95% Cl

C hi-square
(? )

P value

OR

C hi-square
(? )

P value

1.03-1.92
1.70-6.09
1X12-4.60
.492-1.34

4.66(1)
12.95 (1)
4.09(1)
.679(1)

.031
<.001
.043
.410

1.42
3.59
2.27
.817

1.03-1.95
1.90-6.81
.971-5.30
.489-1.36

4.64(1)
15.4(1)
3.58(1)
400(1)

.031
<.001
.058
439

.598-1.54
.942-159
.865-1.68
.950-1.48
-590-.917
1.01-1.81

.029(1)
1.48(1)
1.22 (1)
2.28 (1)
7.48(1)
3.98 (1)

.865
.224
MA
<09
.132
.006
.046

.931
.982
1.06
1.16
.789
1.27

.561-1.54
.803-1.20
.741-1.51
.903-1.48
.608-1.02
.960-1.68

076(1)
032(1)
497(1)
132(1)
3,19(1)
2.80(1)

.782
458
.756
.250
.074
.094

.583-4.04
.380-.271
.343-2.74

.753(1)
.001(1)
•003(1)

.385
.977
.954

1.50
.833
.987

.549-4.12
.303-229
.327-2.97

.630(1)
.126(1)
401(1)

,427
.723
.981

.553-1.45
.936-1.44
3.79-7.44

.208(1)
1.85(1)
354(1)

.648
.174
.072

1.11
1.12
1.14

650-149
.893-1.41
.903-144

181(1)
.987(1)
1,23(1)

.707
.321
.268

1.09-1.74

7.11(1)

.008

1.43

1.12-143

8.08(1)

.004

.295-1.01
•209-.910

3.72 (1)
.489 (1)

.054
.027

.591
•S45

.312-1.12
.259-1.15

2.63(1)
2-56(1)

.105
.109

.736-2.43
.868-850
■48-191
.379-6.93
.481-5.46

.911(1)
2.36(1)
*79(1)
.425(1)
.608(1)

.340
124
.052
.514
.436

1.47
2.13
236
lfi2
1.93

.791-2.72
106-4.31
.055-100
.384-8.62
.505-7.39

1-48(1)
44? (1)
m m
468(1)
•924(1)

.224
.034
.050
.451
.336

.368-1.01
.607-1.98

3.77(1)
.095(1)

.052
.758

.913
1.75

.526-1.58
.820-3.71

.106(1)
2,09(1)

.745
.148

.395-1.04
1.41-3.88
.935-1.25

3.31 (1)
10.7 (1)
1.10(1)

.069
.001
.294

.745
2.03
1.14

.443-1.25
1.20-3.45
.960-1.35

1-23(1)
645(1)
2.21(1)

.267
409
.137

95 % a

. 3P, blood pressure; a , confidence interval; HF, heart failure; LVEF, left ventricular ejection fraction; OR, odds ratio;
.rSH.thyroid-stiinulating hormone.
-'Based On SLUMS screening.
_ 1Adjusted for age, African-American race, Hispanic ethnicity, living alone, tobacco use, and number of prior hospitalisation* .
J n past year.------------------------— •------ ------------------ ■
—■
--------- :---------------— :------- •—-------—------ [_

Implications for Practice
Overall MA w as poor in o u r cohort, w ith subjects both
overtaking a n d und ertak in g th eir m edication. Over
taking m edication h a s n o t received m uch atten tio n in
th e literatu re b u t poses potentially serious patien t
safety issues. In a m ultim orbid population, this
problem is com pounded by polypharm acy prescribed
by m ultiple providers. In o u r study, it w as not
uncom m on to find pa tie n ts w ith several bottles o f the
sam e m edication and taking a tablet from each one.
W e found p a tie n ts m o st often knew th eir m edications
by color a n d sh a p e ra th e r th a n by n am e o r indication.

T his is particularly im p o rta n t in th e VA system
because generic m edications are m ailed to patients'
hom es from a centralized pharm acy. Changes in
vendors used by th e pharm acy frequently resulted in
changes in tablet appearance; patients m ay n o t
recognize th a t th e n ew tab let is actually th e sam e
m edication. Potentially harm fu l m edication errors can
be discovered by careful m edication reconciliation
during clinic visits. However, accurate m edication
reconciliation requires tim e a n d expertise and is
n e ith e r routinely recognized a s a n im p o rtan t p art of
care nor reim bursed in th e c u rre n t m odel of h ealthcare
delivery.1114
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C o g n i t i v e i m p . i i i n i t M i t , u u I m r d i c . i t i o n a d l i n e n r c (n

None
Mild
Dementia
-

A dherence

95% Cl

C hi-square
m

P v a lu e

A dherence

95% <8

81.1%
74.1%
74.0%

77.1-85.0
6M-7&5
65.9-82.1

m
5.22(1)
2.33(1)

Ref
.022
.127

78.1%
70.7%
732%

70.5-852
63.0-78.4
63.3-83.4

C hi-square
m
Ref
528(1)
103(1)

P valu
R tf
.017
.310

3, confidence Interval
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A large proportion of our study participants indi
cated o n th e A dherence E stim ator questionnaire th a t
th ey in te n d e d to adhere to their m edication regim en,
yet overall th e ir actual MA w as poor, a n d clearly the
presence o f Cl contributed to w orsening adherence.
U nfortunately, c u rre n t clinical practice guidelines do
n o t recognize Cl as a risk factor for poor adherence.
C onsideration should be given to screening all p atients
w ith HF for Cl u sin g a tool such as th e SLUMS exam i
nation, w hich can be adm inistered in less th a n 10
m in u tes by regular clinic staff.
In addition, th e m ean score on th e GDS (13.3, sta n 
d ard deviation ± 3.80, n = 249) indicated th a t th e
average participant in th e study w as m ildly depressed.
However, th e prevalence of previously diagnosed
depression in th e study sam ple based on m edical
record review w as only 30.3% (n = 250). T hese findings
confirm th e com orbidity o f depression in p ersons w ith
HF and suggest it m ay b e a n o th er easily m issed diag
nosis in th is population. D epression is k now n to affect
inform ation processing and h a s been show n to be
prevalent and associated w ith w orsened outcom es in
non v eteran s w ith HF.15-26 Therefore, screening for both
Cl a n d depression m ay be o f particular im portance in
veteran s w ith HF.

population in an u rban com m unity in sou th ern Cal
ifornia, w here p a tie n ts have ready access to m edica
tions via p rescription m edication coverage; th e results
of o u r stu d y m ay therefore n o t be readily generalized
to o th er populations. T here is th e recognized difficulty
in objectively m easuring actual MA w ith th e pill
counting technique. We h a d a higher no n retu rn rate
for cognitively im paired patients for th e pill count.
However, w e predict th a t th ese patients w ould have
h a d a t lea st as poor, if n o t w orse, adherence com pared
w ith th e o th e r subjects w ith Cl w ho did follow up;
th u s, o u r d a ta m ay overestim ate actual MA. T here w as
also a h igh n o n re tu rn rate for cognitively im paired
subjects to re tu rn for fu rth er neuropsychologic testing.
Although th e SLUMS exam ination h a s been validated
in a veteran population as a sensitive screening tool,
any brief screening is n o t considered adequate to
m ake quantitative conclusions about Cl. In addition,
th e association o f Cl w ith African-Am erican race,
although significant, w as b ased on a sm all segm ent o f
th e overall stu d y population a n d therefore should be
interpreted w ith caution. Finally, w e did n o t include
h e alth literacy as p a rt o f th e study design; im paired
h e alth literacy m ay fu rth er affect p a tie n ts’ abilities to
u n d e rstan d a n d c a n y out self-care an d m edication
regim ens.

Implications for Further Research
HF is a chronic disease th a t disproportionately affects
th e elderly a n d p resen ts w ith o th er conditions, such as
diabetes or hypertension. Successful outcom es depend
o n adhering to tre a tm e n t regim ens th a t are often highly
com plex a n d require significant cognitive ability to
comply. O ur findings suggest th a t Cl m ay be a key factor
in clinical success o r failure, and indeed a large portion
o f th e o u tp atien t population w ith HF m ay be affected by
th e im p act o f unrecognized Cl on MA. Further research
is n eeded to develop a n d te s t interventions to im prove
MA by specifically targeting underlying Cl. Consider
a tion should be given to interventions th a t specifically
address p otential problem s w ith verbal learning, verbal
m em ory, a n d delayed verbal m em ory.

Study Limitation*
Our study h a d several im p o rtan t lim itations. It w as
conducted in a predom inantly m ale veteran

C o n c l u sio n s
On th e basis o f our clinical experience a n d previous
studies, w e hypothesized th a t veterans w ith HF would
h ave a high prevalence o f Cl a n d th a t th e presence o f Cl
w ould negatively affect MA. Our study found th a t
unrecognized Cl w as highly prevalent and associated
w ith poorer a dherence to m edication in our sam ple of
older o u tp atien t veterans w ith HF. Verbal learning,
im m ediate m em ory, a n d delayed verbal m em ory w ere
th e cognitive dom ains m o st affected. Our findings
suggest th a t Cl m ay be a key factor in clinical success or
failure in th is challenging population. C onsideration
should be given to screening all veterans w ith HF for Cl
to identify th o se w h o will need additional help w ith
adherence. Further research developing interventions
to im prove MA by targeting underlying problem s w ith
Cl is urgently needed.
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A. Background
A.1 ■Heart failure is a significant burden in the VA health care system.
Heart failure [HF] is a prevalent, costly, chronic, and complex condition that impacts an
increasingly larger number of people a s the population ages. In the VA system,
hospitalizations and encounters for HF are on the rise, reflecting the growing number of
veterans who are impacted by this chronic condition that drastically impacts quality of life
[QOL], morbidity and mortality, and greatly increases expenditures for VA health care. In
2009, over 96,000 hospitalizations in the VA system listed HF a s a diagnosis, a 30%
increase from 2002.1 The CHF QUERI2009 Strategic Plan lists reducing hospitalization
rates, increasing use of care known to prolong survival and improve QOL, and
empowering the patient for self-management a s their top goals.1
A.2. HF outcomes are related to adherence.
Evidence-based medication and lifestyle strategies have shown to decrease mortality
and hospitalizations for HF and improve QOL, and are included in the current published
guidelines that summarize recommended clinical regimens.2,3 However, the successful
implementation of these published guidelines in clinical practice remains challenging.2'4
HF patients tend to be older, with multiple comorbidities, and can find it difficult to follow
complex m anagem ent regimens, resulting in poor adherence and the loss of the proven
benefits of guideline-based care. In fact, not adhering to medication regimens has been
shown to be the most common cau se of HF exacerbations and subsequent hospital
readmissions; a recent trial linked poor adherence (defined a s <80% adherence to HF
medications) to all cau se mortality.5' 14
A.3. Adherence is multifactorial.
Adherence depends on complex patient and healthcare factors.5,8,5,10 Specifically,
medication adherence [MA] refers to both compliance (the extent to which behavior
coincides with health advice; e.g. patients take their medication a s prescribed, such a s
twice daily), and persistence (following treatm ent recommendations over time).0,17 The
World Health Organization’s Multidimensional Adherence Model classifies predictors of
poor adherence into five domains: socio-economic, health care system, therapy,
condition, and patient-related domains.18 However, the factors outlined in this model
explain less than 20% of poor adherence in HF patients, highlighting the need to identify
other important drivers of non-adherence in this population.19,23 O ne relatively
overlooked factor that may influence all of th ese domains is the presence of cognitive
impairment [Cl].
A.4. Cl has been associated with adherence in non-HF populations in prior studies.
Prior studies in the elderly have shown that even mild cognitive dysfunction interferes
with the patient’s ability to adhere to self-care and medication regimens, yet assessm en t
for Cl remains rare in clinical practice.21'23 Cl manifests a s problems with memory,
attention, learning, motor speed, reaction times and executive functioning (i.e., higherorder capacities such a s cognitive flexibility, concept formation, initiation, inhibition,
selective attention, planning, and problem-solving).24 It is clinically intuitive that Cl would
directly lead to poor MA based on the tasks commonly confronting HF patients such a s
learning what pill to take, remembering to take it, and having the dexterity and
sequencing skills to open pill bottles and count tablets. Unfortunately, while the cognitive
processes needed to m anage and take medications often decline with aging, the number
of prescription and nonprescription medications consum ed is likely to increase. Although
the relationship between patient’s cognition and MA appears intuitive, prior studies
evaluating the prevalence of Cl in HF have not evaluated the link between Cl and patient
outcomes, including MA.
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A.5. Cl is common in patients with HF.
Previous studies evaluating Cl in HF patients have documented a high rate of Cl,
ranging from 30-50%.25'32 Most of th ese prior studies were limited to small sam ples of
hospitalized patients, such a s those awaiting heart transplant, and thus not applicable to
the patients seen in everyday clinical practice. However, two recent outpatient studies
also dem onstrated increased incidence of Cl in patients with HF compared to m atched
community controls, consistent with the results found in patients with end-stage HF.24,33
No studies have evaluated Cl in the outpatient veterans with HF, or the association to
MA. Our recently completed CHF QUERI funded pilot study Cognitive Impairment as a
Risk for the Admission-Readmission Cycle seen in Veterans with Heart Failure: Closing
the Adherence Gap 34, examined both the prevalence of Cl in outpatient veterans with

HF and the association of Cl with MA.
A.6. Our CHF QUERI funded study provides the basis for an intervention study to
improve MA.
Our study recruited 251 outpatients with HF at VA Loma Linda Healthcare System
[VALLHCS]; data collected included screening scores for Cl, 9-item demographic
survey, 17-item health survey, 10-item chart review, 7 lab results, 25 neuropsychology
tests, a 9-item medication m anagem ent survey, and a 3-item medication adherence
attitude survey. All subjects were asked to bring in all regularly prescribed medications
for a direct 30-day pill count. Subjects were predominantly male (99%), with a m ean age
of 66 years. Sixty-six percent of subjects had left ventricular ejection fraction of < 40% ,
with the m ean of 37.5% (SD ±16.90, range 10-85). Average number of total
prescriptions per subject w as 7.83 (SD + 3.06, range 1-17).
We found a strikingly high prevalence of undiagnosed Cl in our cohort: 58% (144/250) of
patients had Cl based on the Saint Louis University Mental Status [SLUMS] screening
test; 41.6% scored in the mild Cl range and 16% in the dementia range. Of the cognitive
domains tested, verbal learning, immediate memory, and delayed verbal memory were
found to be the most impaired.
Although all study subjects (both with and without Cl) initially agreed to return for the pill
count, only 67% (168/250) of the enrolled subjects did so. Returning for pill count w as in
itself associated with Cl (OR 2.03,95% Cl 1.20-3.45, x2 =6.85, p=0.009). In the sam ple
participating in the pill count, we found a robust and significant association between the
presence of Cl and MA. MA (calculated to reflect both overtaking and under-taking
regularly prescribed medications) significantly worsened with mild Cl, but interestingly
did not continue to worsen a s Cl increased in severity to the dementia range. Overall,
adherence in the entire cohort w as poor: subjects with no Cl had MA of 81%, those with
mild Cl had MA of 74% (95% Cl 69.6-78.5, x2 5.22, p=0.022), and those with severe Cl
(dementia) had MA of 74% (95% Cl 65.9-82.1, x2 2.33, p=0.127). T hese results suggest
three clinically important findings: Cl is highly prevalent, mild Cl is sufficient to impair
MA, and overtaking medications has an important role in nonadherence.
A.7. Different m easurem ents have been used to estim ate medication adherence.
MA, a s estimated in clinical trials, overestim ates the true adherence in the environment
of usual clinical practice; population-based studies have shown actual adherence to
medications to be a s low a s 40-50%.4,36,38 Medication non-adherence may take multiple
forms, including underdosing, overdosing, self-imposed drug holidays and taking
medication that is not prescribed—all in the sam e patient. Currently, there is no gold
standard used to m easure MA though multiple methods are available, and include
patient adherence questionnaires/diaries, assessing direct or indirect clinical response,
performing pill counts, ascertaining rates of refilled prescriptions, and using electronic
medication monitors.37'42 Pill counts are relatively easy to perform, have been correlated
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with electronic monitors, and have been frequently used in randomized, controlled
clinical trials.4340 Recent clinical trials have used electronic devices, such a s the
Medication Event Monitoring System, which register the date and time when cap s of
medication bottles are removed.14,44,51'63 Such devices have been shown to be valid
instruments in measuring adherence in research settinas, but are impractical to use
when measuring adherence with multiple medications.14,20,54
A.8. Prior studies designed to improve adherence due to patient-dependent factors have
not had a sustained effect in patients with HF.
Multiple interventions have been tested to improve MA; however, a system atic review by
Haynes et al. found that m ost interventions studied in patients with HF did not have a
large or sustained effect, and the ones that had any effect at all were complex and
involved multiple disciplines.16 Intervention trials in patients with HF have used
counselingby apharm acist, home nursing interventions, and extensive education
program s.1
Many of these interventions have shown improved MA, but the effect
typically disappeared once the intervention w as over.
A.9. Targeted interventions are more likely to be efficient and cost effective,
The existing studies have approached interventions to improve MA b ased on
stratification on existing primary diagnosis (for example, HF, coronary d isease or
hypertension) rather than targeting specific determinants of non-adherence such a s Cl.
In fact, many of the interventions tested in HF populations in prior studies were patientaction driven and therefore likely to fail in patients who have Cl. The high prevalence of
Cl dem onstrated in our recent study suggests that this may be an important contributing
factor in MA in patients with HF. Unfortunately, there are few if any studies providing
guidance on how to effectively improve MA in this vulnerable population. Traditional
interventional strategies are not effective, or do not have a sustained effect, suggesting
that new innovative methods are needed to improve outcomes.
W e propose that interventions designed to improve MA by addressing underlying
problems posed by Cl are likely to be more effective and less costly a s specific
populations would be targeted to receive the appropriate level of intervention. An ideal
intervention to improve MA in patients with Cl would be technology-driven, easy to
implement, sustainable in the long-term, and cost-effective. It would also be targeted at
the specific cognitive domains affected in patients with HF such a s learning and
memory.
Based on Wu criteria for optimal adherence (the cutoff of adherence predicting eventfree survival in outpatients with HF was 88%),14 our findings suggest that the 74%
adherence found in our patients with mild Cl offers a rich target for intervention to
improve outcom es to directly m eet the CHF QUERI goals of reducing hospitalization
rates, increasing use of care known to prolong survival and QOL, and empowering the
patient for self-management.
B. Automated Medication Dispensing Device TAMDPl.
O ne novel and promising technology is based on the use of the AMDD.8 ,8 This device
is designed to improve MA and target several cognitive domains of memory, attention
(reminding the patient to take medications on time), fine motor skills, sequencing,
processing speed (selecting and manipulating medication bottles) and executive
functioning (helping patients to decide which pills they should take). This device is able
to hold up to 60 do ses of medications in pre-filled cups, to be programmed a s needed
based on the frequency of dosing. It is equipped with an alarm mechanism that alerts the
patient to take the medications; when the patient p ushes the button on the device, it will
dispense the medications. If medications are not dispensed at the appropriate interval
(within 90 minutes of the pre-set time), the patient and the study staff will receive an
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autom ated phone call from a centralized monitoring center. The monitoring center will
continue to ring the telephone until a dedicated button is pushed on the phone, indicating
the call w as received. The study staff will attempt to telephone the subject to remind
them to take their medication; and to problem-solve a s needed.
The AMDD will be set up in the subject’s home, and training will be provided to the
subject and family by study staff. The medication dispenser will be pre-filled with the
subject’s prescribed cardiac medications by a home health nurse once a month (home
health nurse will be hired on a contract basis from the agency currently providing home
care to patients at VALLHCS).
This device w as selected for several reasons: 1) it targets the cognitive domains of
memory, attention, sequencing, fine motor skills, processing speed, and executive
functioning; 2) the locking mechanism promotes medication safety and prevents patient
’’overtaking” their medications (which w as found to be a significant problem in our current
study); 3) it provides m eans whereby patients with Cl may be empowered to remain
independently in their home; 4) the centralized monitoring system will add another
aspect to the collectable adherence data (when and how many times the phone calls
were prompted by missed doses); 5) it is programmable to prompt patients to take
medications with food, to check their blood glucose level, use their inhaler, etc.; 6) it has
an eariy-dispense feature to allow for planned doses if the subject is away from home; 7)
it is in alignment with the VA’s philosophy of utilizing commercially available, off-the-shelf
technology; 8) it has the potential for future device modification to allow expanded use,
such a s collecting physical param eters (blood glucose, weight, blood pressure) and to tie
in with the VA's commitment to health informatics, disease management, and care
coordination/home telehealth so the veteran maintains independence.68

Q-SPWtffc Aim?.
AIM 1. Feasibility.
Our purpose is to a s s e s s the feasibility of using the AMPP in veterans with HF and Cl.
W e powered the study to detect the “su ccess rate” of the AMDD, defined a s both patient
acceptance and a clinical response to the AMDD. Clinical response is defined a s a 9%
increase in patient-ievel adherence and, alternatively, a 7% increase in medication-level
adherence. The 9% and 7% represent, respectively, the adjusted m ean differences in
patient-level and medication-level adherence rates between patients with no Cl and mild
Cl in our finished study.
Our specific aims will therefore be the following:
Aim 1A. M easure the percentage of patients with diagnosed HF who qualify for the
AMDD based on our study inclusion/exclusion criteria (qualifying rate).
Aim 1B. M easure the percentage of qualified patients who agree to participate (consent
rate).
Aim 1C. M easure the percentage of enrolled and consenting patients able to place the
AMDD in their hom es and use it appropriately (user rate).
Aim 1D (11. M easure the percentage of patients using the AMDD who have a positive
clinical response to the AMDD over a one-month period (patient-level response rate).
Aim ID (2). M easure the likelihood that the patient using the AMDD responds to the
AMDD for a given medication over a one-month period (medication-level response rate).
Aim 1E. M easure the percentage of patients who both accept and respond to the AMDD
(success rate).

AIM 2. Medication Adherence (exploratory analytical aim).
W e will calculate the improvement of MA in patients with HF and Cl who use the AMDD,
based on a 30-day pill count following the introduction of the AMDD.

AIM 3. Medication Adherence (qualitative aim).
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Aim 3A. Describe the reasons why enrolled patients were not able to use the AMDD.
Aim 3B. Describe patient satisfaction with the AMDD.
Aim 3C. Quantitatively describe the time spent to set up and fill the AMDD.

AIM 4, Clinical outcom es (exploratory aim).
Clinical outcomes, including readmissions for HF, are going to be important in any larger
interventional study; we therefore included m easurem ents of th ese outcom es in our pilot
study for exploratory reasons.
Aim 4A. Measure changes in physical param eters, such a s blood pressure, heart rate,
and weight.
Aim 4B. M easure changes in clinical/functional outcomes, such a s New York Heart
Association (NYHA) functional class, serum B-type natriuretic peptide (BNP) levels, and
diuretic usage.
Aim 4C. Measure changes in utilization (emergency departm ent visits and
hospitalizations).
The conceptual basis for our study is explained by the model presented below. This
model shows Cl a s one of the factors associated with adherence, with adherence
predicting clinical outcomes for HF such a s readmissions, QOL, morbidity and mortality.
We propose that an intervention with the AMDD in patients with Cl and HF will target
adherence directly, and also indirectly by having a moderating effect on the link between
Cl and adherence. This pilot study will m easure a total effect and will not distinguish
between moderating and direct effect.

Figure 1. Model showing proposed levels of AMDD effect on adherence and
INTERVENTION WITH AMDD
Moderatina effect

Direct effect

V
COGNITIVE IMPAIRMENT

ADHERENCE

---------------------------------Readmissions and ED visits
i Non-CI factors affecting adherence
f
!-------------------------------------------J

OUTCOMES
Quality of life
Mortality

D. Research Design and Methods.
D.1. Study Design.
This study is designed a s a feasibility study testing an intervention, with the subjects
serving a s their own controls. Figure 2 outlines the flowsheet describing the study
design.
D.2. Study Setting.
The study will be conducted at the VALLHCS, Loma Linda, CA, which serves a
population of 246,000 veterans. This is an urban setting with an ethnically mixed
population.

Figure 2. Study flowsheet.
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D-3, Study
Screening patients for the study

Patients who meet Inclusion criteria are enrolled

DATA COLLECTION 1
30-day pill count for adherence

^88% adherence
AMDD issued, run-in trial of 1 month
Use of AMDD for 1 month

DATA COLLECTION 2
30-day pill count for adherence

>88%
§ adherence
T
I

No AMDD,
observation only

Population,
This study will enroll
patients with HF and
Cl from outpatient HF
clinic. If inclusion and
exclusion criteria are
satisfied, patients will
be invited to
participate, informed
consent will be
obtained, and patients
will be enrolled.
Inclusion/Exclusion
Criteria;
1. Outpatients with a
diagnosis of HF
supported by
established criteria.
2. Cl a s m easured by
SLUMS and defined
a s a score of <27 in a
person with high
school education of
<25 in a person with
less than high school
education.

3. English-speaking.
4. Age 18 or older.
5. Able to provide consent.
6. Able to provide a stable home environment for at least 90 days that will enable the
use of the AMDD (i.e. electricity, stable surface to place the dispenser on, and telephone
access).
7. Able to be trained on the use of the AMDD.
8. Stable on at least two standard HF medications for at least one month.
Exclusion Criteria:
1. Life expectancy < 6 months.
2. Patients whose medications are already administered by family m em bers or a
caregiver.
Projected enrollment is 5-6 subjects a month over nine months, for a total of 50 subjects.

nmnf.8t SMy fipwehret,

D.4. Data Collection.
D.4.a. Screening for Cl.
SLUMS will be used to screen for Cl and will be administered by HF clinic staff. The
SLUMS exam is a brief screening m easure to a s s e s s cognition.09,70 This 30-point, 11item clinician-administered interview scale w as developed by researchers at the St.
Louis VAMC and normed in a veteran population. It contains norms adjusted for patient
education levels, and quantifies the level of impairment a s none, mild, or impairment
consistent with dementia, with the score of <27 considered to be consistent with Cl in a
person with high school education or <25 in a person with less than high school
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education. A comparison study of the SLUMS exam with the well-known Mini-Mental
Status Examination [MMSE] in veterans suggested that the SLUMS exam w as superior
to MMSE in detecting mild Cl and impairment in executive functioning.71'74
Trained research staff administered the SLUMS exam to 250 subjects in our prior study;
all subjects were able to complete the test with an average time of completion of 7.1
minutes (range 4-15). Similar to the MMSE, the SLUMS exam can also be administered
by front-line clinicians. To dem onstrate feasibility of screening using SLUMS in a busy
clinic setting with a wide range of patients, we asked the RN and LVN staff in our clinic
to u se this tool to screen patients for Cl during the check-in process. The staff w as
trained in a brief 15-minute insen/ice on how to accurately administer and score the
SLUMS. The opportunity to administer the SLUMS exam w as well received by the
nursing staff; they noted that the time used to administer the SLUMS exam was
equivalent to obtaining an accurate set of vital signs and checking VA clinical reminders.
This exam was administered by the clinic nurses to 28 patients in an average of 7.2
minutes over the course of one week.
D.4.b. Other data collection.
During the initial interview, we will collect basic demographic data, such a s the patient’s
gender, age, education level, living arrangement, and social support. Physical
parameters collected at baseline and after the use of the AMDD include blood pressure
(as m easured by a standard manual cuff), heart rate (as m easured by direct auscultation
of the heart with a stethoscope), and weight (as m easured by the sam e scale routinely
used in the HF clinic). Clinical/functional data collected at baseline and after the use of
the AMDD include NYHA class (as determined by a health care practitioner from patient
interview),2 BNP (standard lab test), and change in diuretic usage (determined by chart
review).
D4.c. Quantitative data collection for feasibility.
As outlined in Aim 1, to test feasibility, we will m easure the percentage of patients
qualifying for the AMDD (qualifying rate), consenting to participate (consent rate), able to
place the AMDD in their hom es and use it appropriately based on the instructions (user
rate).
D.4.d. Qualitative data collection for feasibility.
Patient, family member and home health nurse interviews will be used to describe the
reasons for not being able to use the AMDD, and patient satisfaction with the AMDD.
T hese interviews will be qualitative in nature and conducted by the investigators using
an interview guide designed to capture participant decision-making and identify barriers
to use of the AMDD. The interview guide questions will cover four topics based on the
MacCat-CR Interview format: understanding, appreciation, reasoning, and expressing a
choice. Interview results will be analyzed using open and axial coding.73 We will also
collect data on time spent to set up and fill the AMDD (average time per patient per
month spent by the home health nurse).
D.5. Targeted intervention.
D.5.1. Baseline medication adherence.
Baseline MA to prescribed cardiac medications will be m easured by a 30-day pill count.
On study day one, subjects will bring in their medications for the initial pill count. They
will continue with usual care, and return on study day 30 +/- 3 days for the baseline 30day pill count.
D.5.2. Intervention with AMDD.
Only patients with MA <88% will continue with the AMDD part of the study, with the goal
of 50 patients recruited to test AMDD. Based on data from our completed study, we
estim ate that we will need to recruit 80 subjects for the first pill count in order to arrive at
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the goal of 50 subjects with MA of <88%. W e chose to test the AMDD only in subjects
with baseline impaired MA in order to ensure the effect of the intervention in a population
that is most likely to benefit. Subjects selected to continue will be assigned the device to
use for 60 days (one month to familiarize the study subjects with the device, one month
to collect outcome data). The 30-day pill count will be repeated on study day 90.
D.6. Statistical Analysis.
Descriptive statistics include m eans, frequencies, variance, and simple correlations. To
determine patients’ response to the AMDD, we will define patient-level and medicationlevel adherence rates by taking the absolute difference between the amount of pills
prescribed and amount of pills taken, a s shown:

MA,

with MA, a s patient-level adherence for patient / over all cardiac medications, and MAVa s
medication-level adherence for subject / and cardiac medication j= 1 , ..., nb with P,j> 0
pills prescribed and T#z 0 pills taken. This approach penalizes su ccess whenever
subjects either over-, or under-took a prescription. All rates (qualifying, consent, user
rates and “success” rates will be computed and tested for significance b ased on a
binomial distribution, and by bootstrapping 10,000 sam ples. Mean AMDD response rates
will be captured from the constant term to Generalized Linear Models (patient-level) and
Generalized Estimating Equations (medication-level) with robust standard errors and
logit linking function to account for repeated medication-level nesting within patient. For
exploratory analyses, m ean centered covariates may be added to adjust rates to
account for differences in medication class, patient demographic (age, ethnicity/race),
and clinical factors (Cl severity, illness duration).
Phone bank data from the centralized monitoring system will be used to establish and
describe patterns of nonadherence (how many times did the patient need reminder calls;
did the reminder calls have an identifiable pattern).
D.7. Power calculation.
Sample size power for n=50 w as computed at 95% and 99% confidence intervals based
on our pilot data (n=251) for three anticipated patient- and medication-level su ccess
rates and an estimated IntraClass Correlation = .414 with Cl 95%[.368, .457],
F(1315,1315) a 2.410, p<.001, and m ean 5.23 cardiac meds/patient (SD=1.808).
Estimates were computed from 100,000 parametric bootstrapped sam ples simulating
study condition for 50 completed subjects, a s reported below in Table 1. In summary, we
can detect a 20% clinically relevant su ccess rate in patient-level adherence with a twotailed test a t an alpha=.05 with 99% power.

Table 1. Expected Confidence Intervals for Anticipated Su ccess Rate for 50
Subjects.
20% Success
Rate

50% Success Rate

80% Success Rate

Medication-level
adherence
95% Confidence
Interval

12.5%

28.1%

39.6%

60.4%

71.9%

87.5%

Targeted Intervention to Improve Medication Adherence in Cognitively
Impaired Patients with Heart Failure
99% Confidence
interval

48

10.4%

31.3%

36.5%

63.5%

68.8%

89.6%

10.0%

32.0%

36.0%

64.0%

68.0%

90.0%

6.0%

36.0%

32.0%

68.0%

64.0%

94.0%

Patient-level adherence
95% Confidence
inten/ai
99% Confidence
Interval

D.8, Data Management,
All data will be double entered and checked for consistency, with inconsistencies
resolved by the study coordinator and principal investigator [PI]. Data are entered into
secure electronic password-protected files residing in the VA in a locked office,
accessible only to approved study investigators and the study coordinator. To maintain
patient privacy and confidentiality, data will be de-identified prior to statistical analysis by
assigning subjects a study number. A linkage log relating subject nam e and last four
digits of their social security number to the study number will be kept in a secure location
in the HF clinic. After validation, de-identified data will be transferred to an S P S S format
R esearch Ready file using our 3-part data accounting system designed to ensure data
safety and security, e a s e of access, information integrity, efficiency of use, and accuracy
and consistency of data interpretation.76 All data will be processed on VA site, OI&T
approved facilities through the VALLHCS Center for Advanced Statistics in Education.
D.9. Limitations,
The results of this study may not b e generalizable to all patient groups with HF,
specifically, nonveteran patients, women, or patients with clinically less severe HF who
were not referred to HF clinic. Our study is limited by single center location, which may
give rise to selection bias.

E. Research Context/Implementation Plan,
Contributing to the body of implementation science is an objective of the CHF QUERI s
strategic plan, and in keeping with that objective, our research is designed to directly
facilitate the implementation of evidence-based strategies known to improve outcom es in
patients with HF. By addressing underlying Cl, the AMDD could produce reliable and
persistent improvements in MA in a population where traditional strategies have fallen
short. This commercially available ‘off the shelf’ device, if found feasible, could be
readily implemented into clinical practice to m eet the immediate needs of the VA.
However, in order for any novel intervention to be widely implemented by clinicians,
effective case-finding to identify the population at risk is essential to improve outcom es
and control costs. In order to identify cognitively impaired veterans more at risk for poor
MA, a simple yet reliable screening tool for Cl that can be used in clinical setting is of
critical importance. W e have shown that the SLUMS exam, which w as developed by VA
clinician/researchers and validated in a veteran population, may be quickly and
accurately administered by front-line staff in a busy clinic setting. In addition, SLUMS
provides a cut-off score to identify mild Cl, which w as shown to be sufficient to
negatively impact MA in our pilot study.
The next goal will be to utilize results of this research to inform future studies examining
whether early identification of, and intervention for, Cl in patients with HF will result in
improved adherence and outcomes. The future trial would test implementation of a
range of multidisciplinary interventions, including the AMDD for select populations. The
study design would include methods to identify which patients are more likely to benefit
from which intervention since the adherence may be moderated by presence of factors
other than Cl. If future efforts show that targeted interventions are effective in improving
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outcom es in HF patients with Cl, it will provide impetus to implement screening for Cl in
HF m anagem ent guidelines, and potentially change the current standard of practice.
Finally, this approach to patients with Cl is likely not unique to populations of patients
with HF, and may be generalized to populations with other chronic illnesses, such a s
diabetes or hypertension. Thus we envision that the results from our studies examining
patients with Cl and HF can be used in the future in other large veteran populations.

F. Barriers and Facilitators.
As a feasibility study, our proposed research aims are designed to identify, both
quantitatively and qualitatively, the practical issues that will need to be addressed during
clinical implementation of the AMDD outside a research context. Health care barriers in
implementing the intervention with AMDD include cost of the device, time spent by
clinical staff and the availability of home health nursing. Patient barriers include living
situation, social and cultural issues, willingness to use the device, and lack of family
support. Formal evaluation of these barriers is built into our study design. Future barriers
in implementing the screening for Cl include time spent in clinic for screening, clinician
aw areness and clinician “buy-in” (whether the clinician is convinced that screening for Cl
will change the outcomes).
Formal analysis of direct and direct costs would be integral to future, larger trials; this
pilot study will provide preliminary data about the costs of the intervention, a s well a s
unforeseen barriers.
Possible facilitators to overcome barriers include seeking support of local and national
VA administrators, enlisting local opinion leaders in raising clinicians’ aw areness of the
problem, and familiarizing the clinicians with the data a s outlined in the dissemination
plan.

G. Evaluation olan/Plseemlnatlon.
We will evaluate the results of this study in light of published data prior to dissemination.
Rogers’ Diffusion of Innovation Theory suggests that new ideas are spread by
individuals, largely by imitation.1,77 W e will utilize local opinion leaders at our facility a s
well a s the CHF QUERI network to dissem inate results of this pilot study. The results of
this pilot trial will be presented at national cardiology meetings and published on the
QUERI website. W e also expect to publish a manuscript with the findings in a peerreviewed cardiology journal to ensure wider dissemination of the data.

H. Project Management Plan.
H.1. Study Timeline.

Table 2. Gantt Chart for study timeline.
Activity
Preparation and submission
of documents to IRB
Hire/train study coordinator
Preparation of study
documents and database
Enrollment of subjects
Data collection
Data analysis
Data presentation
Write manuscripts
Write final report

Month
1

Month 2-7

Month 8-10

Month 1112

----------

—
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H.2. Resources Required.
This is a single center study and will be conducted at VALLHCS, utilizing existing space
in the cardiology and research sections. The PI and co-PIs will have a cc e ss to statistical
resources and the library at the VALLHCS and at Loma Linda University.
The Philips medication dispenser will be contracted at the regular market rate of $85.00
for installation, and $75.00 per month for monitoring. W e will not enter into any special
financial arrangem ent with the Philips company to avoid financial conflict of interest, and
to allow us to retain ownership of all data collected.
H.3. Research Team.
The project team is multidisciplinary and includes:
Principal Investigator (Name removed) MD. MPH is currently working a s a staff
cardiologist at VALLHCS. (Name removed) has been active in cardiology outcomes
research with special interest in patients with atrial fibrillation and HF. As PI, sh e will be
responsible for the study and will coordinate the work among the co-investigators and
the study coordinator. She will oversee all the asp ects of the study, including the
regulatory aspects, patient recruitment, and adherence to the proper consent process,
data collection and data management. She will be responsible for analyzing and
interpreting the results of the study with the project team.
Co-lnvestiaator Lee Ann Hawkins. RN. MSN. FNP is the HF Clinic nurse practitioner at
the VALLHCS. She is pursuing her PhD and is active in HF research. As co
investigator, sh e will be responsible for the day-to-day asp ects of the study, training the
study coordinator and working closely with him or her to ensure that operations are
performed according to schedule and according to study protocol. She will also fill in for
the PI responsibilities when the PI is on vacation or not available.
Co-Investigator and Senior Research Consultant (Name removed). PhD is a Research
Professor of Medicine at the Loma Linda University School of Medicine and Director of
the C enter for Advanced Statistics in Education at the VALLHCS. He is a well-published
senior HSRD career scientist who will be involved in the design and analysis part of the
study. As co-investigator, he will serve in an advisory capacity, based on his prior
experience in multivariable analysis in numerous HSR&D research projects.
Co-lnvestiaator and Senior R esearch Consultant (Name removed). MD. MS is currently
the director of Diabetes Services at the VALLHCS. He has been PI or co-PI on
numerous research projects. As co-investigator, he will serve in an advisory capacity,
based on his prior experience in chronic diseases outcomes research.
Co-investiaator (Name removed!, PhD is a Neuropsychologist who conducts
neuropsychological assessm en ts for a variety of patients with cognitive disorders at
VALLHCS and has prior research experience in the a rea of Cl. She will serve in an
advisory capacity to help interpret the results of this study and design future studies.
Study Staff. (Name removed). Pharm P is currently working a s the Research Pharmacist
and Infectious D isease Clinical Pharm acist at the VALLHCS. He will serve in an advisory
capacity in collecting and interpreting the pill count data.
The study coordinator will be hired prior to the start of the study. He or sh e will be
responsible for screening potentially eligible patients for the study, collecting study data,
coordinating the setup of the AMDD with the Philips company and with the home health
nurse, coordinating and conducting appointments for labwork and performing pill counts.
The study coordinator will receive alerted telephone calls from the Philips central
monitoring station, and initiate calls to the subjects a s appropriate. The study coordinator
will also perform chart review with the supervision of the PI and co-PIs, assist with
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preparation and maintenance of all regulatory documentation, and enter all clinical data
to Excel database.

1.

H eidenreich P. C H F QUERI S trateg ic Plan. 2009;
http://w vw .aueri.research.va.Q ov/about/strategic_plans/chf.pdf.

2.

Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the
ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in
Adults A Report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines Developed in Collaboration With the
International Society for Heart and Lung Transplantation. J Am Coll Cardiol. Apr 14
2009;53( 15):e 1-e90.
LindenfeldJ, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure
Practice Guideline. J Card Fail. Jun;16(6):e 1-194.
Heidenreich PA. Patient adherence: the next frontier in quality improvement. Am J Med.
Jul 15 2004;117(2): 130-132.
DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient Adherence and Medical
Treatment Outcomes: A Meta-Analysis. Medical Care. 2002;40(9):794-811.
Esposito D, Bagchi AD, Verdier JM, Bencio DS, Kim MS. Medicaid beneficiaries with
congestive heart failure: association of medication adherence with healthcare use and
costs. Am J Manag Care. Jul 2009;15(7):437-445.
Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on
hospitalizations and mortality in heart failure. J Card Fail. Aug;17(8):664-669.
Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with
cardiovascular disease who underuse medications because of cost: a longitudinal
analysis. Med Care. Feb;48(2):87-94.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in
cardiovascular outcomes. Circulation. Jun 16 2009;119(23):3028-3035.
Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence,
knowledge, and skills with emergency department visits by adults 50 years or older with
congestive heart failure. Am J Health Syst Pharm. Oct 1 2004;61(19):2043-2049.
Mockler M, OToughlin C, Murphy N, et al. Causes and consequences of nonpersistence
with heart failure medication. Am J Cardiol. Mar 15 2009;103(6):834-838.
Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized
cardiovascular risk factor. MedGenMedL 2007;9(3):58.
Murray MD, Tu W, Wu J, Morrow D, Smith F, Brater DC. Factors associated with
exacerbation of heart failure include treatment adherence and health literacy skills. Clin
Pharmacol Ther. Jun 2009;85(6):651-658.
Wu JR, Moser DK, Chung ML, Lennie TA. Objectively measured, but not self-reported,
medication adherence independently predicts event-free survival in patients with heart
failure. J Card Fail. Apr 2008;14(3):203-210.
Delamater. Improving Patient Adherence. Clinical Daibetes. 2006 2006;23(2):71-71,7577.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing
medication adherence. Cochrane Database Syst Rev. 2008(2):CD000011.
George J, Elliott RA, Stewart DC. A systematic review of interventions to improve
medication taking in elderly patients prescribed multiple medications. Drugs Aging.
2008;25(4):307-324.
Sabate E. Adherence to long-term therapies: evidence for action. Geneva: WHO: World
Health Organization. 2003.

3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

Targeted Intervention to Improve Medication Adherence in Cognitively
Impaired Patients with Heart Failure
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.

52

van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and
possible solutions. IntJ Cardiol. Apr 10 2008;125(2):203-208.
Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence using a
multidimensional adherence model in patients with heart failure. J Card Fail. Sep
2008; 14(7):603-614.
Arlt S, Lindner R, Rosier A, von Renteln-Kruse W. Adherence to medication in patients
with dementia: predictors and strategies for improvement. Drugs Aging.
2008;25( 12): 1033-1047.
Cotrell V, Wild K, Bader T. Medication management and adherence among cognitively
impaired older adults. J Gerontol Soc Work. 2006;47(3-4):31-46.
Hayes TL, Larimer N, Adami A, Kaye JA. Medication adherence in healthy elders: small
cognitive changes make a big difference. J Aging Health. Jun 2009;21(4):567-580.
Sauve MJ, Lewis WR, Blankenbiller M, Rickabaugh B, Pressler SJ. Cognitive
impairments in chronic heart failure: a case controlled study. J Card Fail. Feb
2009;15(1):1-10.
Bennett SJ, Sauve MJ. Cognitive deficits in patients with heart failure: a review of the
literature. J Cardiovasc Nurs. Jul-Aug 2003;18(3):219-242.
Clark AP, McDougall G. Cognitive impairment in heart failure. Dimens Crit Care Nurs.
May-Jun 2006;25(3):93-100; quiz 101-102.
Cohen MB, Mather PJ. A review of the association between congestive heart failure and
cognitive impairment. Am J Geriatr Cardiol. May-Jun 2007; 16(3): 171-174.
Lackey J. Cognitive impairment and congestive heart failure. Nurs Stand. Jul 14-20
2004; 18(44):33-36.
Pressler SJ. Cognitive functioning and chronic heart failure: a review of the literature
(2002-July 2007). J Cardiovasc Nurs. May-Jun 2008;23(3):239-249.
Pullicino PM, Wadley VG, McClure LA, et al. Factors contributing to global cognitive
impairment in heart failure: results from a population-based cohort. J Card Fail. May
2008;14(4):290-295.
Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in
heart failure: a systematic review of the literature. Eur J Heart Fail. May 2007;9(5):440449.
Zuccala G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bemabei R. Left
ventricular dysfunction: a clue to cognitive impairment in older patients with heart
failure. J Neurol Neurosurg Psychiatry. Oct 1997;63(4):509-512.
Pressler SJ, Subramanian U, Kareken D, et al. Cognitive deficits in chronic heart failure.
Nurs Res. Mar-Apr 2010;59(2):127-139.
Silvet H HL. Cognitive Impairment as a Risk for the Admission-Readmission Cycle seen
in Veterans with Heart Failure. 2010.
Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority
for health care reform. N Engl J Med Apr 29 2010;362(17):1553-1555.
Osteiberg L, Blaschke T. Adherence to medication. N Engl J Med Aug 2005;353(5):487497.
Christensen DB, Williams B, Goldberg HL Martin DP, Engelberg R, LoGerfo JP.
Assessing compliance to antihypertensive medications using computer-based pharmacy
records. Med Care. Nov 1997;35(11):1164-1170.
Farmer KC. Methods for measuring and monitoring medication regimen adherence in
clinical trials and clinical practice. Clin Ther. Jun 1999;21(6): 1074-1090; discussion
1073.
Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and
cardiovascular events in patients with stable coronary heart disease: the heart and soul
study. Arch Intern Med. Sep 10 2007; 167(16): 1798-1803.
Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug
exposure assessment. J Clin Epidemiol May 1997;50(5):619-625.

Targeted Intervention to Improve Medication Adherence in Cognitively
Impaired Patients with Heart Failure
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

S3

Smith H, Hankins M, Hodson A, George C. Measuring the adherence to medication of
elderly patients with heart failure: Is there a gold standard? Int J Cardiol Jul IS 2009.
Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records:
methods, validity, and applications. J Clin Epidemiol. Jan 1997;50(1): 105-116.
Botelho RJ, Dudrak R, 2nd. Home assessment of adherence to long-term medication in
the elderly. J Fam Pract. Jul 1992;35(l):61-65.
Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy
records, and pill counts with electronic monitoring of adherence to antihypertensive
therapy. Med Care. Sep 1999;37(9):846-857.
Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for monitoring and
counseling patients with hypertension. Impact on medication adherence and blood
pressure control. Am J Hypertens. Apr 1996;9(4 Pt l):285-292.
Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and
pharmacy claims data to measure medication adherence in the elderly. Ann
Pharmacother. Jul-Aug 1998;32(7-8):749-754.
Laporte S, Quenet S, Buchmuller-Cordier A, et al. Compliance and stability of INR of
two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost.
Mar 2003;89(3):458-467.
Lee JK. How should we measure medication adherence in clinical trials and practice?
Ther clin risk manag. Aug 2007;3(4):685-690.
Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, et al. Efficacy of a home blood
pressure monitoring programme on therapeutic compliance in hypertension: the
EAPACUM-HTA study. J Hypertens. Jan 2006;24(1): 169-175.
Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of a multidisciplinary
intervention on medication compliance in elderly patients with congestive heart failure.
Am J Med. Sep 1996;101(3):270-276.
Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance
with medication regimens. Drugs. Mar 1995;49(3):321-327.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is
medication taken as prescribed? A novel assessment technique. JAMA. Jun 9
1989;261(22):3273-3277.
Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication
adherence in heart failure: a randomized trial. Am Intern Med. May 15
2007;146(10):714-725.
Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for
medication adherence in heart failure. Am Heart J. Feb 2009;157(2):285-291.
Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home
follow-up of hospitalized elders: a randomized clinical trial. JAMA. Feb 17
1999;281(7):613-620.
Naylor MD, Brooten DA, Campbell RL, Maislin G, McCauley KM, Schwartz JS.
Transitional care of older adults hospitalized with heart failure: a randomized, controlled
trial. J Am GeriatrSoc. May 2004;52(5):675-684.
Schnipper JL, Roumie CL, Cawthon C, et al. Rationale and design of the Pharmacist
Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study. Circ
Cardiovasc Qual Outcomes. Mar;3(2):212-219.
Anderson C, Deepak BV, Amoateng-Adjepong Y, Zarich S. Benefits of comprehensive
inpatient education and discharge planning combined with outpatient support in elderly
patients with congestive heart failure. Congest Heart Fail. Nov-Dee 2005; 11(6):315-321.
Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A
multidisciplinary intervention to prevent the readmission of elderly patients with
congestive heart failure. N Engl J Med. Nov 2 1995;333(18):1190-1195.
Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a
randomized controlled trial. Arch Intern Med. Sep 25 2006;166(17): 1822-1828.

Targeted Intervention to Improve Medication Adherence in Cognitively
Impaired Patients with Heart Failure
61.
62.
63.
64.

65.
66.
67.
68.

69.
70.

71.
72.
73.

74.

75.
76.
77.

54

Coleman EA, Smith JD, Frank JC, Min SJ, Parry C, Kramer AM. Preparing patients and
caregivers to participate in care delivered across settings: the Care Transitions
Intervention. JAm Geriatr Soc. Nov 2004;52(11):1817-1825.
Hansen RA, Dusetzina SB, Song L, Gaynes BN, Tu W, Murray MD. Depression affects
adherence measurement but not the effectiveness of an adherence intervention in heart
failure patients. JAm Pharm Assoc (2003). Nov-Dee 2009;49(6):760-768.
Laramee AS, Levinsky SK, Sargent J, Ross R, Callas P. Case management in a
heterogeneous congestive heart failure population: a randomized controlled trial. Arch
Intern Med. Apr 14 2003;163(7):809-817.
Peters-Klimm F, Muller-Tasch T, Schellberg D, et al. Rationale, design and conduct of a
randomised controlled trial evaluating a primary care-based complex intervention to
improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case
Management). BMC Cardiovasc Disord. 2007;7:25.
Powell LH, Calvin JE, Jr., Mendes de Leon CF, et al. The Heart Failure Adherence and
Retention Trial (HART): design and rationale. Am Heart J. Sep 2008;156(3):452-460.
Rondinini L, Coceani M, Borelli G, et al. Survival and hospitalization in a nurse-led
domiciliary intervention for elderly heart failure patients. J Cardiovasc Med
(Hagerstown). May 2008;9(5):470-475.
Philips. Phillips Automated Medication Dispenser Website. [Web Page]. 2010;
http://www.managemvDills.com/content/How PMD Works.
Darkins A, Ryan P, Kobb R, et al. Care Coordination/Home Telehealth: the systematic
implementation of health informatics, home telehealth, and disease management to
support the care of veteran patients with chronic conditions. Telemed J E Health. Dec
2008;14(10):1118-1126.
Banks WA, Morley JE. Memories are made of this: recent advances in understanding
cognitive impairments and dementia. J Gerontol A Biol Sci Med Sci. Apr 2003;58(4):314321.
Morley JE TN. Saint Louis University Mental Status Examination (SLUMS). Aging
Successfully. 2002;XII.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res. Nov
1975; 12(3): 189-198.
Juby A, Tench S, Baker V. The value of clock drawing in identifying executive cognitive
dysfunction in people with a normal Mini-Mental State Examination score. CMAJ. Oct
15 2002; 167(8):859-864.
Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr
Psychiatry. Jun 2000;15(6):548-561.
Tariq SH, Tumosa N, Chibnall JT, Perry MH, 3rd, Morley JE. Comparison of the Saint
Louis University mental status examination and the mini-mental state examination for
detecting dementia and mild neurocognitive disorder--a pilot study. Am J Geriatr
Psychiatry. Nov 2006;14(11):900-910.
Appelbaum PS G, T. MacCAT-CR: MacArthur Competence Assessment Toolfor Clinical
Research. Sarasota, FL: Professional Resource Press; 2001.
Kashner TM, Hinson R, Holland GJ, et al. A data accounting system for clinical
investigators. J Am Med Inform Assoc. Jul-Aug 2007;14(4):394-396.
Rogers E. Diffusion of Innovations. New York: Free Press; 2004.

55

Title Page
Title: Health literacy and use of a pictorial medication sheet to improve adherence.
Short title: Health Literacy and Medication Adherence
Article Type: Research Paper
Authors:
Lee Ann Hawkins RN; PhD(c), NP
Author affiliations:
VA Loma Linda Healthcare System, Loma Linda, CA
Submission includes:
Abstract: 207 words
Keywords: 5
Abbreviation list
Text: 15 pages
3 Tables
2 Figures
38 References

Disclosures: No disclosures
Funding support: VA CHF QUERI pilot grant: RRP 12-198
Corresponding author:
Lee Ann Hawkins
VA Loma Linda Healthcare System
Cardiology Section, 111C
Loma Linda, CA 92357
Email: LeeAnn.Hawkins@va.gov
FAX: 909-583-6709
Telephone: 909-583-6156
Mobile telephone: 951-217-161

Abstract

Background: Interventions to increase medication adherence are needed to improve
heart failure (HF) outcomes. A recently completed study tested a pictorial medication
sheet to improve adherence in veterans with HF and cognitive impairment. While health
literacy (HL) scores were not collected as part of that study, they were part of the patient
medical records. This new data-based study examines potential mediating effects of HL
on observed medication adherence in that study.
Objectives: (a) describe the level of HL, (b) determine relationships between HL and
selected clinical and demographic variables, and (c) estimate the relationships between
HL, key variables, and medication adherence in the study sample.
Methods: In a secondary analysis, HL scores from medical records were analyzed with
data from the original pilot study using conventional statistics and structural equation
modeling.
.Results: 27 subjects with a mean age of 65.3 years (SD 8.2, range 45-80) had evaluable
data. HL was less than adequate in 19% of the sample. HL scores were strongly
correlated with cognition. HL did not significantly affect relationships between study
covariates (cognition scores, depression, number of medications) and medication
adherence.
Conclusions: HL scores are associated with cognitive function scores. More research is
needed to evaluate the prevalence and effect of poor HL on medication adherence in
veterans with HF.
Key Words: Medication non-adherence, cognitive dysfunction, veterans, heart failure,
health literacy

57

Abbreviations:
Cl: Cognitive Impairment
HF: Heart Failure
HL: Health Literacy
IRB: Institutional Review Board
NYHA: New York Heart Association
RMSEA: Root Mean Square Error of Approximation
SEM: Structural equation modeling
SLUMS exam: Saint Louis University Mental Status examination
VA: Veteran’s Health Care Administration
Introduction
Heart failure (HF) is an epidemic confronting the American healthcare system;
currently 5.8 million people in the United States have HF, and this number is projected to
grow as the population ages.1'3 HF presents as a complex chronic disease characterized
by frequent exacerbations often resulting in emergency department visits and hospital
readmissions. This excessive admission-readmission cycle is costly in terms of poor
patient outcomes as well as healthcare expenditures, particularly within the Veterans’
Health Care System (VA), the largest integrated healthcare system in the United States.
Within the VA, 20% of HF patients are readmitted within 30 days, contributing to the
total annual cost estimates of over $37 billion for HF care in the United States.4 The
majority of HF readmissions are related to medication non-adherence and are therefore
preventable.3'9 Thus identification of and intervention for factors contributing to poor
medication adherence is key to reducing readmissions and improving outcomes.10,11

Factors related to poor medication adherence
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Adherence is a complex issue and may be conceptualized as one of the dynamic
and multidimensional activities that comprise self-care. Self-care is particularly important
in a chronic illness such as HF that is primarily managed at home by the patient him or
herself. Conceptual frameworks and theoretical models describe HF self-care as an
19 1^

iterative process requiring a series of thoughtful decisions on the part of the patient. ’

Factors that affect decision making such as difficulty in understanding and remembering
directions, or the presence of depression, impair the patient’s ability to engage in
successful self-care.12,13 The capability to make appropriate decisions is especially
critical in negotiating the complex medication regimen HF patients are often required to
follow. Because HF is primarily a disease of the elderly and presents with co-morbid
illnesses, this complexity is compounded by polypharmacy prescribed by multiple
providers, and the fact medications are subject to change with each hospital
readmission.8,2
One important, yet clinically under-recognized factor affecting a patient’s ability
to correctly take medication is the presence of cognitive impairment (Cl)- It is clinically
intuitive that impairment in cognitive domains such as memory, verbal fluency, attention,
motor speed, and executive functioning (e.g. higher-order capacities such as planning and
problem-solving) would negatively affect a person’s ability to correctly obtain and take
medications.14,15 Cl has been shown to be a prevalent co-morbid condition in outpatients
with HF, who may have a four-fold risk of developing Cl compared to the general
population.15' 17 A recent study of outpatient veterans with HF demonstrated a high
prevalence (58%, n=251) of clinically unrecognized Cl that was significantly associated
with poorer medication adherence.14
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Another factor commonly associated with non-adherence to medication is poor
health literacy (HL), broadly defined as the degree to which individuals obtain and
understand basic information in order to make appropriate decisions and negotiate the
1

fl

healthcare system to manage their well-being. In America, low HL is considered to be a
prevalent and clinically under-recognized problem in the general population; up to 57%
of patients with HF may have poor HL.18'21 One study assessed HL in 1,786 veterans
and reported a lower prevalence of poor HL than is generally described in the civilian
population; specifically 8.3% of subjects had inadequate and 11.8% had marginal HL
skills.22 However, little is known about the prevalence of poor HL in veterans with HF, or
the effect of HL on medication adherence in cognitively impaired veterans with HF.
Depression is yet another condition that has been associated with less than
adequate self-care, and worsened outcomes such as hospital readmissions and mortality,
in persons with HF.23,24 Studies have shown depression to be common in persons with
HF, with prevalence rates conservatively estimated at about 26%, or 2 to 3 times higher
than in the general population.24 Although examining the effect of depression on HF
outcomes has received increasing attention in the literature, this condition often remains
clinically under-recognized. 23,24 For example, in a study of 250 veterans with HF, the
average subject was found to be mildly depressed, yet only 30% of the sample had been
formally diagnosed.14

Interventions to Improve Adherence
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Unfortunately there remains a general lack of awareness on the part of providers,
as well as no incentive in the current model of healthcare, to screen elderly HF patients at
risk for poor medication adherence at clinic visits.23,26 Interventions to improve
adherence that rely on traditional models of patient education are likely to fail in this
population. There is a paucity of tested interventions designed to improve outcomes by
targeting key determinants of poor adherence such as Cl and poor HL.23’27 Interventions
that have shown improvement in adherence to date were complex and did not result in
sustainable outcomes.28'30
Cognitive impairments such as impaired memory and verbal fluency are
associated with poor HL and are commonly found in elderly persons with HF.

Indeed,

the close association of poor HL with Cl has received increased attention in the literature;
a recent study proposed that current measures of HL are actually rudimentary
assessments of cognition.32 Hence, interventions to improve adherence in patients with
low HL should also reduce demands on cognitive abilities. The commonly accepted view
that simply utilizing S^-grade language and a few illustrations for health information will
not help low-literacy patients if the pictures must be mentally integrated to be
understood.19,28
As a first step to address this gap, a pilot study (TARGET) was designed to target
Cl as an underlying cause of medication non-adherence. The TARGET study enrolled 36
subjects with known Cl from an outpatient veteran HF clinic and tested the effectiveness
of a customized pictorial medication sheet along with an optional alarmed pillbox to
improve medication adherence.33 The primary outcome, medication adherence, was
measured from sequential direct 30-day pill counts, using subjects as their own controls.
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Secondary outcomes included feasibility and tolerability determined by qualitative
interviews.
A major limitation in the TARGET study was that no information on HL was
collected as part of the study itself. HL may actually have mediated the relationship
between key independent variables (including the intervention) and the outcome measure
of medication adherence.
Therefore the purpose of this study was to estimate the relationships between
participant’s HL scores (obtained from the medical record), and key variables, including
the outcome, medication adherence, using data obtained from the TARGET study.
The specific aims of this study included:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of relationships between HL and selected
clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that HL and other key variables
(including the intervention) on post intervention medication adherence in cognitively
impaired veteran outpatients with HF.

Methods
The study employed a retrospective, correlational, cross-sectional design using
data from the completed TARGET pilot study and the participants’ medical records.
Approval was obtained from the institutional review board (IRB) prior to data collection.
The data were de-identified prior to analysis. The TARGET study was conducted at a
large metropolitan Veteran’s Administration facility that serves an urban population of
246,000 veterans in southern California.
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Sampling Procedure
The sample included subjects (n=36) from the TARGET pilot study. These
subjects were originally recruited as a convenience sample from an outpatient VA
medical center HF clinic between November 2011 and June 2012. All were 18 years old
or older, had an established clinical diagnosis of HF, and had screened positive for Cl
using the Saint Louis University Mental Status (SLUMS) exam34 prior to entrance into
the study. SLUMS is an education-adjusted, 30-point clinician-administered screen for Cl
that has been validated in a veteran population and shown to be more sensitive to
detecting mild Cl than the more familiar MMSE.35,36
In order to participate in testing the pictorial medication sheet and alarmed
pillbox, participants were required to speak and read English, follow simple directions, be
able to see, and have the manual dexterity to take their own medications. Thus, persons
with severe functional limitations, acutely decompensated HF, dementia requiring a
caregiver, or severe mental illness, such as active schizophrenia, were excluded. Subjects
were also excluded if they had a life expectancy of less than six months. The TARGET
study was designed as a pilot study to test feasibility and effectiveness of the
intervention. Thus, no power analysis was conducted.
Data Collection Procedures
For this current study, subject’s data were retrospectively obtained from the
TARGET study data and the electronic medical record, and placed into a database with
all personal identifiers removed. This database was compiled by the investigator and
audited for completeness and veracity by another researcher. The new database included
HL scores from the subject’s medical record and medication adherence scores,
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demographic, and clinical data from the TARGET study. Demographic data included age,
gender, race, living arrangements (alone or with others), and educational level. Clinical
data included the presence of comorbid depression, participant’s SLUMS score, and
number of prescribed medications. These demographic and clinical data were selected as
having potential influence on medication adherence in the study sample, based on
review of relevant literature. Subject ID numbers were assigned sequentially, and all data
was subsequently de-identified.
Details of the TARGET study have been reported elsewhere, but are summarized
here for relevance to the current investigation.33The TARGET study consisted of four
study visits. Subjects were enrolled during a routine visit to the investigator’s clinic. At
study visit one, subjects were asked to bring in all their regularly prescribed medications
for a pill count. Subjects returned in approximately 30 days for visit two. At visit two, a
repeat pill count was performed to determine baseline adherence. During this visit the
subject received a customized pictorial medication sheet consisting of images of their
current medications in full color and dose range (i.e. the image showed two and one-half
tablets if they were to take two and one-half tablets) in columns for morning, noon, and
evening. Brief descriptions of the medication name, indication and dose were also
included. A sample medication sheet is displayed in Figure 1. Subjects were also offered
an optional CADEX Pocket Pill Box (ePill LLC) with 4 vibrating daily alarms. Subjects
returned for repeat 30-day pill counts at visit three (giving them a month to adjust to the
intervention), and visit four, to determine their post-intervention adherence. At each visit
the subject had a brief physical exam and New York Heart Association (NYHA)
functional class determined by the investigator. Qualitative data regarding the feasibility
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and acceptability of the intervention were collected in patient interviews at each visit
using standardized questions.
Measures
In the current study, data related to HL were derived from participants’ scores on
the Short Test of Functional Health Literacy for Adults (S-TOFHLA) documented in the
medical record.37 This instrument was derived from the longer Test of Functional Health
Literacy for Adults (TOFHLA) designed to assess the ability to perform basic reading
and numerical tasks in a healthcare setting.38 The S-TOFHLA has been shown to be
valid, reliable, and easily administered in a clinical setting.37 The S-TOFHLA includes a
timed (7 minute) reading comprehension test using the modified Cloze procedure; the
patient reads common medical instructions that have every 5th to 7th word in a passage
omitted and is asked to select a word from 4 multiple-choice options to fill in the blank
spaces. Possible scores range from 0-36, with 0-16 scored as “inadequate”, 17-22
“marginal” and 22-36 “adequate” health literacy37’38 In addition, the S-TOFHLA
includes a 17-item, timed (10 minute) numeracy subscale that tests the practical ability of
patients to comprehend medication prescription labels, results of blood glucose tests,
clinic appointment slips, and financial assistance for healthcare information. The
numeracy subscale is scored in a weighted manner according to the test manual to create
a final score ranging from 0-50.38 These HL measures had been administered to patients
in the HF clinic as part of usual care since January 2011, and scores recorded on progress
notes maintained in the VA electronic medical record. There is no evidence in the
literature that HL scores as assessed by S-TOFHLA change over time.

As background, the data on the dependent variable for this study, medication
adherence score, was obtained for each prior study subject from their post-intervention
30-day pill count collected as part of the prior TARGET study. The TARGET study
medication adherence scores were determined in the following manner: to capture both
overtaking and undertaking medication, a delta was determined for each prescribed
medication by computing the absolute difference between the number of pills taken
versus the prescribed number over the 30-day period for each pill count. The delta values
for each medication were summed for each individual subject, divided by the total
number of pills prescribed, subtracted from 1, and finally multiplied by 100 to obtain an
adherence score expressed as a percentage. Thus, a value of 100% indicated all pills were
taken correctly. A value of 85% meant that 15% of prescribed pills were either not taken,
or overtaken, or a combination of both. All currently prescribed medications were
included in the pill counts, except medications taken on an “as needed” (pm) basis,
injectables, and inhaled medications. Over-the-counter medications were also excluded.
Statistical Analysis
Data analysis was performed using Statistical Package for the Social Sciences v.
20 (SPSS) (IBM Corporation) and Mplus v.7 software (Afplus, 2012). A p-value of .05 or
less was determined as significant. Frequency distributions for each variable were
examined for normal distribution characteristics, missing data, and outliers.
Descriptive statistics, including measures of central tendency and frequency, were
employed to address study aim one. Study aim two was explored using bivariate
correlational tests appropriate to the level of measurement (e.g. Spearman’s rho for
ordinal data and Pearson’s r for interval or ratio level data). To achieve aim three,
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structural equation modeling (SEM), specifically a path mediation model, was utilized for
analysis.
Results
Study characteristics. Thirty-six (36) subjects were enrolled in the TARGET
study. Of these, two subjects died before completing the study; one subject was
hospitalized for a prolonged period and was not able to return in a timely manner for
study visits; one subject dropped out due to transportation issues; three subjects had
unusable adherence data (they attended all study visits but did not bring in medication
consistently enough to be counted); and two simply did not return for scheduled study
visits despite repeated telephone and written messages asking them to do so. Thus, 27
subjects completed the study with usable data; 26 (96%) were male, with an average age
of 65.3 years (SD 8.2, range 45-80). Baseline characteristics of the study sample are
presented in Table 1.
Prevalence of poor HL. The mean reading HL (S-TOFHLA) score for the sample
was 29.92 (n=26, SD 7.27, range: 15-36) and the mean numeracy HL score was 43.40
(n=27, SD 9.36, range 15-50). Specifically, 19.2% of the entire sample had less than
adequate HL (S-TOFHLA score <23). Only one subject did not complete the reading HL
instrument and therefore this was treated as missing data with no imputations for the
analysis.
Correlational analysis. The strength and direction of relationships between
reading HL, numeracy HL, and demographic and clinical variables were explored as
shown in Table 2. Few significant relationships were found in this study. Specifically,
age was negatively associated to both reading HL (r = -.407, p < .05) and numeracy HL
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(r = -.499, p < .05). This suggests a moderate contribution of age to the variability in HL
scores (lvalues of .16 and .25, respectively). SLUMS exam scores were strongly
associated with both reading HL (r = .804, p < .01) and numeracy HL (r = .545, p c.Ol).
This suggests a moderate to strong contribution of cognition to the variability of health
literacy scores

values of .65 and .30, respectively).

Structural equation model. A path mediation model was constructed after a set of
preliminary analyses including descriptive data examination for outliers, missing data and
non-normality were conducted. Three exogenous covariates chosen for the model were
based on review of relevant literature and included SLUMS score, number of prescribed
medications, and history of depression. Reading and numeracy HL scores were
hypothesized to mediate the effects of the covariates on the dependent endogenous
variable, medication adherence.
Analysis of post-intervention data using the path model revealed that path
coefficients were in the hypothesized direction. SLUMS score was associated with
reading HL (standardized coefficient 4.995, p - 0.000) and numeracy HL (standardized
coefficient 3.842, p = 0.000); history of depression was negatively associated with
numeracy HL (standardized coefficient -2.513, p = 0.012); and the number of prescribed
medications had a direct, negative association with medication adherence (standardized
coefficient -2.515, p - 0.012). Model fit was evaluated and found to be acceptable by
Chi-square (0.755, df 1, p = 0.385) and a Root Mean Square Error of Approximation
(RMSEA) estimate of 0.000,90% Cl 0.000 -0.473, and probability of RMSEA <= .05:
0.430. The path model is presented in Figure 2.
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An attractive aspect of path modeling is the ability to estimate indirect, or
mediating, effects as well as direct and total effects among variables. In relation to study
aim number three, Table 3 presents the estimated indirect effects of HL scores for the
covariates on post-intervention medication adherence. Neither reading nor numeracy HL
scores reached statistical significance as mediating the effects of SLUMS score ip =
0.459 and 0.604, respectively), history of depression (p = 0.862 and 0.608, respectively),
or number of medications ip = 0.575 and 0.716, respectively) on medication adherence.
Discussion
This study had three important findings: (1) The prevalence of poor HL in the
study sample was lower than generally described in the civilian population, (2) cognitive
function was strongly correlated with measures of HL, and (3) HL did not mediate the
outcome of medication adherence in the interventional TARGET pilot study.
We found HL to be less than adequate in 19% of our study sample, which is
strikingly similar to the 20% reported by Griffin in a study of over 1700 veterans (not
limited to those with HF).22 Poor HL in the general population with HF has been
reported to be as high as 57%.21 Further study is warranted to better understand the
prevalence of poor HL in veterans with HF.
Our finding that the subjects’ cognitive scores strongly correlated with HL scores
is supported by current trends in the literature. For example, the cognitive domains of
memory and verbal fluency were related to HL in a study of 414 older communitydwelling adults.31 Intriguingly, these two domains were found to be the most affected in
a study of veterans with HF and Cl.14 In the LitCog study (n=882), associations between
poor HL and performance of healthcare tasks diminished once cognitive ability was
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controlled for, and the authors concluded that measures of HL actually identified
differences in cognition.32 This study is one of the first to examine the effect of HL on an
intervention to improve adherence that was modified to address patient’s cognitive
limitations.
The finding that HL did not mediate the effect of the covariates Cl, depression,
and number of medications, on medication adherence in the TARGET study is not
surprising for several reasons. Foremost, the TARGET interventional medication sheet
was not specifically designed to address poor HL, although it does incorporate
medication images with simple text. Next, the low prevalence of poor HL in the study
sample may have affected the outcome. Finally, there may be covariates other than the
three chosen for analysis that may have had a stronger interaction with poor HL.
Implications for Practice
It is important for clinicians to identify those patients at risk for poor medication
adherence so that extra resources may be allocated to help them. This risk profile will
need to be tailored to individual patient populations, and include screening for prevalent
conditions that have been shown to contribute to poor adherence in that particular
population. For the busy clinician screening HF patients for Cl and depression may have
better yield than trying to screen for poor HL. The design of future interventions to
improve adherence should take into account all the cognitive demands placed on the
patient rather than simply skills in reading and numeracy.
Strengths and Limitations of Methods
There are important limitations to this research design. The sample size is small,
drawn from a pilot feasibility study, and was selected as a convenience sample from the

investigator’s HF population of predominantly elderly Caucasian male veterans from an
urban southern California VA medical center. The VA system offers ready access to
prescription medication coverage. Therefore, the results may not be readily generalized to
other populations. There is no data available to know if HL scores obtained from the STOFHLA instrument and recorded in the past medical record would change over time.
Finally, the study sample size was theoretically inadequate for full SEM analysis.
Although not a panacea for low sample size, the bootstrapping option (as was done in this
study) may be employed for exploratory analysis. Indeed, we did run our path analysis
with an additional 500 bootstrapping sample iterations, and did not fmd substantial
differences in the significance testing.

Conclusions
Consistent with the current literature, the prevalence of poor HL in our sample
population of veterans with HF and Cl was lower than generally found in the civilian
population; and HL scores were found to be strongly associated with cognitive function
scores. HL did not mediate the effect of key variables on the outcome, medication
adherence. More research is needed to evaluate the prevalence and effect of poor HL
upon adherence in veterans with HF and Cl.
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Table 1. Characteristics of the Study Sample.
Variable

Subjects n=27

Age (y) mean ± SD (range)
Male gender
Race:
African American
Caucasian
Hispanic
Educational level:
Less than high school
High school diploma
College or above
Living arrangements:
Alone
With others
History of depression
SLUMS score1mean ± SD (range)
Number of prescribed med.
mean ± SD (range)

65.3 ±8.2 (45-80)
26(96.3%)
3(11.1%)
20(74.1%)
4(14.8%)
4 (14.8%)
9 (33.3%)
14 (51.9%)
11(40.7%)
16 (59.3%)
13 (48.1%)
22.90 ±2.93 (13-26)
14.44 ±5.93 (5-27)

Med: medication, SD:
standard deviation, SLUMS: Saint Louis University Mental Status exam, S-TOFHLA: Short form test of
functional health literacy for adults.
1SLUMS screening is positive for mild cognitive impairment for score < 27 in persons with high school
diploma or <25 in persons who did not complete high school. Screen is considered positive for severe
impairment consistent with dementia for score <21 for persons with high school diploma or <20 for persons
who did not complete high school.
2S-TOFHLA is scored from 0-36, with 0-16 considered inadequate, 17-22 marginal, and 22-36 adequate
health literacy.
3Numeracy is scored from 0-50.
4Prescribed medications for the participant at the start of study, obtained from chart review.

Table 2.
Direction and Strength of Relationship of HL to Selected Variables
Reading HL
n=26

Numeracy HL
n=27

Age
-.499
Pearson Correlation -.407
.008
.039
Sig. (2-tailed)
Race
-.386
Spearman’s Rank
-.255
Order
.047
.209
Sig. (2-tailed)
Educational Level
.159
.315
Spearman’s Rank
Order
.109
.437
Sig. (2-tailed)
SLUMS Score1
.804
.545
Pearson Correlation
.003
.000
Sig. (2-tailed)
Depression
-.218
-.106
Point-biserial
.607
.276
Sig. (2-tailed)
# Medications2
.007
Pearson Correlation
.205
.971
.127
Sig. (2-tailed)
Adherence Pre3
Pearson Correlation -.210
.070
.730
.303
Sig. (2-tailed)
Adherence Post4
.085
Pearson Correlation -.046
.674
.825
Sig. (2-tailed)
Saint Louis University Mental Status exam
2Number of prescribed medications for each subject
3Medication adherence pre-intervention in TARGET pilot study
4 Medication adherence post-intervention in TARGET pilot study

Table 3.
Indirect Effects of HL Scores on Medication Adherence
HL did not mediate the effect of cognitive impairment, depression, or number of
medications on medication adherence after exposure of the subjects to the intervention.

Two-tailed P-value

SLUMS score
History of depression
Number of medications

Indirect effect
post-intervention1’2
-0.121
0.005
-0.022

Numeracy HL Score
SLUMS score
History of depression
Number of medications

0.065
-0.046
0.009

0.604
0.608
0.716

Reading HL Score

1Estimated regression coefficient for indirect effect
2Standardized (Z-score)

0.459
0.862
0.575
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Figure 1. Interventional Pictorial Medication Sheet

Patient, Test

4/27/2012
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Heart
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One, twice a day

Heart
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Half, once a day

Cholesterol

Gabapentin
300mg
TWo, 3x per day

Neuropathy pain
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0.4mg
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One, once a day
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Pag®1.
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Figure 2. Path mediation model

slu m

.324 (.862]

-.481 (2.683^1
hxdep

-.148(3.973)

adallp

.139 (.267)

viodel fit: Chi-square (0.755, df 1, p = 0.385); Root Mean Square Error of Approximation (RMSEA)
estimate of 0.000,90% Cl 0.000 -0.473, and probability of RMSEA <= .05:0.430.

Figure 1. Three exogenous covariates are shown in the boxes on the left; slums = Saint
Louis University Mental Status Exam (cognitive scores); hxdep =history of depression as
determined by chart review; nummedsp =number of medications prescribed for each
subject at the start of the study. Health literacy scores are shown as the mediating
variables in the boxes in the middle of the model: stofhla =Short Test of Functional
Health Literacy for Adults (reading HL), and Numeracy (numeracy HL). The endogenous
dependent variable is shown in the box to the far right: adallp =post-intervention
medication adherence. The numbers on the paths represent unstandardized regression
coefficients with standard errors in parenthesis.
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Dissertation Summary and Conclusion
This dissertation presented elements of my program of research in the field of
medication adherence, cognition, and health literacy in persons with heart failure (HF).
The overarching goal of this research is to improve HF outcomes by effecting change in
the current model of care by ensuring patients at risk for poor medication adherence are
identified and given extra support and assistance.
The background, review of the current literature, and theoretical framework
relative to this research was included in Chapters 1 and 2. Chapter 3 presented the
methodology for the study protocol that was proposed and conducted as the focus of this
dissertation.
The three research papers contained in this dissertation represent the natural flow
of a developing program of research. Initially, based on a problem noted in clinical
practice, research was conducted that revealed unrecognized cognitive impairment that
significantly worsened medication adherence in a sample of veterans with HF. This is
reported in the first manuscript, Cognitive Impairment (Cl) and Medication Adherence in
Outpatients with Heart Failure, which has been accepted for publication (Hawkins, 2012).
The results of that research informed the next two papers. The second document is a grant
proposal: Targeted Intervention of Improve Medication Adherence in Cognitively
Impaired Patients with Heart Failure. This is a project to test the feasibility and
effectiveness of an automated medication-dispensing device to help patients with HF and
Cl take their medications correctly at home. The grant was funded and enrollment began
November 2012. The final paper presents the results in manuscript form of the protocol
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described in Chapter 3: Health Literacy and Use of a Pictorial Medication Sheet to
Improve Adherence.
These research efforts have added to the body of existing nursing knowledge, and
will provide a foundation for a continuing program of research. The Veterans
Administration has compiled a library of 30,000 medication images, however the use of a
pictorial medication sheet has not been tested in the veteran population (Echt, McConnell
& Trettin, 2012). This dissertation research is one of the first to examine the effect of HL
on a pictorial intervention to improve adherence in veterans with HF and Cl. In addition,
testing an intervention targeted towards underlying Cl and poor HL operationalizes the
Self-Care of HF model (Riegel, 2008) in a unique way.
Conclusion
It is important for clinicians to identify those patients at risk for poor medication
adherence so that extra resources may be allocated to help them. This risk profile will
need to be tailored to individual patient populations, and include screening for prevalent
conditions that have been shown to contribute to poor adherence in that particular
population. For the busy clinician screening HF patients for Cl and depression may have
better yield than trying to screen for poor HL. The design of future interventions to
improve adherence should take into account all the cognitive demands placed on the
patient, as well as other key determinants of poor adherence, rather than simply skills in
reading and numeracy.
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